Please note: this is a data archive. For the most recent data and statistics, please see the the main Data and statistics section of our website.
To get started, select one of the categories below.
You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.
Data: statistical bulletin 2012 [ARCHIVE]
Please note: this is a data archive. For the most recent data and statistics, please see the the main Data and statistics section of our website.
The interactive version of the Statistical bulletin should appear in your browser window in a matter of seconds. If, however, you continue to see either this text and/or a loading status message, the interactive version may not be functioning correctly. This could be due to your browser's settings, the version of browser you're using, or a technical error on our side. Please begin by consulting the Explanatory notes and help page but feel free to contact us for further assistance (online[a]emcdda.europa.eu — dont't forget to replace '[a]' with '@' before sending the message).
Please note you can also access all statistical elements and data on the listing of all statistics page.
About the Statistical bulletin
The Statistical bulletin is published yearly by the EMCDDA and provides access to the most recent statistical data relating to the drugs situation in Europe. Statistics are organised by category. In addition to the statistical tables and graphs, an overview of the data is provided for each category.
Data: statistical bulletin 2012 [ARCHIVE]
Please note: this is a data archive. For the most recent data and statistics, please see the the main Data and statistics section of our website.
The Statistical bulletin is published yearly by the EMCDDA and consists of over 400 tables and 100 graphs of the most recent available data on the drug situation in Europe, all available to view interactively on screen and download in Excel format.
The information covers a broad range of areas including the most recent estimates of treatment and prevalence, information on focused studies of drug related infectious diseases and of problem drug use, levels of drug related deaths, drug related crime in the form of drug seizures, types of offence, price, purity and use in prison, and country responses to the drug situation in Europe.
The Statistical bulletin is the result of close interaction between focal points and experts at the country level, and the EMCDDA at the European level. A highlight this year is the inclusion of data from the most recent European School Survey Project on Alcohol and Other Drugs (ESPAD) which provides an important insight into drug use at school level across Europe.
About the data
The information provided here may be freely reused, provided it is reproduced accurately, not presented in a misleading way and that all sources are acknowledged (see the help page for full details).
Please note: this is a data archive. For the most recent data and statistics, please see the the main Data and statistics section of our website.
| Type | Category | Prefix | Number | Part | Title | Part title | Alias | Reference | File name |
|---|---|---|---|---|---|---|---|---|---|
| Table | DLO | dlotab1 | 1 | i | Drug law offences, 1995 to 2010 | Number of reports of offences | /stats12/dlotab1a | dlotab1a | Table-DLO-01-parti.xml |
| Table | DLO | dlotab1 | 1 | ii | Drug law offences, 1995 to 2010 | Number of reports of persons | /stats12/dlotab1b | dlotab1b | Table-DLO-01-partii.xml |
| Table | DLO | dlotab1 | 1 | iii | Drug law offences, 1995 to 2010 | Methodological notes | /stats12/dlotab1c | dlotab1c | Table-DLO-01-partiii.xml |
| Table | DLO | dlotab2 | 2 | i | Offence types in reports for drug law offences, 2009 or 2010 | Number and percentage of all reports for drug law offences | /stats12/dlotab2a | dlotab2a | Table-DLO-02-parti.xml |
| Table | DLO | dlotab2 | 2 | ii | Offence types involved in reports for drug law offences: methods of percentages calculation for drug law offences | Methodological notes | /stats12/dlotab2b | dlotab2b | Table-DLO-02-partii.xml |
| Table | DLO | dlotab3 | 3 | i | Drug types in reports for drug law offences, 2009 or 2010 | Number and percentage of all reports for drug law offences | /stats12/dlotab3a | dlotab3a | Table-DLO-03-parti.xml |
| Table | DLO | dlotab3 | 3 | ii | Drug types in reports for drug law offences | Methodological notes | /stats12/dlotab3b | dlotab3b | Table-DLO-03-partii.xml |
| Table | DLO | dlotab4 | 4 | i | Drug law offences related to drug use or possession for use, 2003 to 2010 | Number and percentage | /stats12/dlotab4a | dlotab4a | Table-DLO-04-parti.xml |
| Table | DLO | dlotab4 | 4 | ii | Drug law offences related to drug use or possession for use, 2003 to 2010 | Methodological notes | /stats12/dlotab4b | dlotab4b | Table-DLO-04-partii.xml |
| Table | DLO | dlotab5 | 5 | i | Drug law offences related to drug supply, 2003 to 2010 | Number and percentage | /stats12/dlotab5a | dlotab5a | Table-DLO-05-parti.xml |
| Table | DLO | dlotab5 | 5 | ii | Drug law offences related to drug supply, 2003 to 2010 | Methodological notes | /stats12/dlotab5b | dlotab5b | Table-DLO-05-partii.xml |
| Table | DLO | dlotab6 | 6 | i | Cannabis-related offences, 2003 to 2010 | Number and percentage of all drug law offences | /stats12/dlotab6a | dlotab6a | Table-DLO-06-parti.xml |
| Table | DLO | dlotab6 | 6 | ii | Cannabis-related offences, 2003 to 2010 | Methodological notes | /stats12/dlotab6b | dlotab6b | Table-DLO-06-partii.xml |
| Table | DLO | dlotab7 | 7 | i | Heroin-related offences, 2003 to 2010 | Number and percentage of all drug law offences | /stats12/dlotab7a | dlotab7a | Table-DLO-07-parti.xml |
| Table | DLO | dlotab7 | 7 | ii | Heroin-related offences, 2003 to 2010 | Methodological notes | /stats12/dlotab7b | dlotab7b | Table-DLO-07-partii.xml |
| Table | DLO | dlotab8 | 8 | i | Cocaine-related offences, 2003 to 2010 | Number and percentage of all drug law offences | /stats12/dlotab8a | dlotab8a | Table-DLO-08-parti.xml |
| Table | DLO | dlotab8 | 8 | ii | Cocaine-related offences, 2003 to 2010 | Methodological notes | /stats12/dlotab8b | dlotab8b | Table-DLO-08-partii.xml |
| Table | DLO | dlotab109 | 109 | i | Number of reports for drug law offences, 1985 to 2010 | Number of reports of offences | /stats12/dlotab109a | dlotab109a | Table-DLO-109-parti.xml |
| Table | DLO | dlotab109 | 109 | ii | Number of reports for drug law offences, 1985 to 2010 | Number of reports of persons | /stats12/dlotab109b | dlotab109b | Table-DLO-109-partii.xml |
| Table | DLO | dlotab109 | 109 | iii | Number of reports for drug law offences, 1985 to 2010 | Methodological notes | /stats12/dlotab109c | dlotab109c | Table-DLO-109-partiii.xml |
| Figure | DLO | dlofig1 | 1 | Indexed trends in reports for drug-related offences by broad type of offence in the EU Member States, 2005–10 | /stats12/dlofig1 | dlofig1 | Table-DLO-g01-parti.xml | ||
| Figure | DLO | dlofig2 | 2 | Offence types in reports for drug law offences in the EU Member States, Croatia and Norway, 2009 or 2010 | /stats12/dlofig2 | dlofig2 | Table-DLO-g02-parti.xml | ||
| Figure | DLO | dlofig3 | 3 | Indexed trends in reports for drug law offences by type of drug in the EU Member States, 2005–10 | /stats12/dlofig3 | dlofig3 | Table-DLO-g03-parti.xml | ||
| Figure | DLO | dlofig4 | 4 | Indexed trends in reports for offences related to drug use or possession for use in the EU Member States, 2005–10 | /stats12/dlofig4 | dlofig4 | Table-DLO-g04-parti.xml | ||
| Figure | DLO | dlofig5 | 5 | Indexed trends in reports for offences related to drug supply in the EU Member States, 2005–10 | /stats12/dlofig5 | dlofig5 | Table-DLO-g05-parti.xml | ||
| Table | DRD | drdtab0 | 0 | Drug-induced deaths recorded in EU Member States according to national definitions: sources and bibliographic references | /stats12/drdtab0 | drdtab0 | Table-DRD-00-part0.xml | ||
| Table | DRD | drdtab1 | 1 | i | Summary of characteristics of the deceased in drug-induced deaths according to national definitions | Demographic characteristics, 2010 or last year with available information | /stats12/drdtab1a | drdtab1a | Table-DRD-01-parti.xml |
| Table | DRD | drdtab1 | 1 | ii | Summary of characteristics of the deceased in drug-induced deaths according to national definitions | Numbers of drug-induced deaths and toxicology, 2010 or last year with available information | /stats12/drdtab1b | drdtab1b | Table-DRD-01-partii.xml |
| Table | DRD | drdtab1 | 1 | iii | Summary of characteristics of the deceased in drug-induced deaths according to national definitions | Demographic characteristics and toxicology, 1990 or earliest year with available information | /stats12/drdtab1c | drdtab1c | Table-DRD-01-partiii.xml |
| Table | DRD | drdtab2 | 2 | i | Number of drug-induced deaths recorded in EU Member States according to national definitions | Total drug-induced deaths, 1995 to 2010 | /stats12/drdtab2a | drdtab2a | Table-DRD-02-parti.xml |
| Table | DRD | drdtab2 | 2 | ii | Number of drug-induced deaths recorded in EU Member States according to national definitions | Male drug-induced deaths, 1995 to 2010 | /stats12/drdtab2b | drdtab2b | Table-DRD-02-partii.xml |
| Table | DRD | drdtab2 | 2 | iii | Number of drug-induced deaths recorded in EU Member States according to national definitions | Female drug-induced deaths, 1995 to 2010 | /stats12/drdtab2c | drdtab2c | Table-DRD-02-partiii.xml |
| Table | DRD | drdtab2 | 2 | iv | Number of drug-induced deaths recorded in EU Member States according to national definitions | Total drug-induced deaths under the age of 25 years, 1995 to 2010 | /stats12/drdtab2d | drdtab2d | Table-DRD-02-partiv.xml |
| Table | DRD | drdtab2 | 2 | v | Number of drug-induced deaths recorded in EU Member States according to national definitions | Totals and indexes, 1995 to 2010 | /stats12/drdtab2e | drdtab2e | Table-DRD-02-partv.xml |
| Table | DRD | drdtab3 | 3 | Number of drug-induced deaths recorded in EU Member States and Norway according to EMCDDA standard definition 'Selection B', 1995 to 2010 | /stats12/drdtab3 | drdtab3 | Table-DRD-03-part0.xml | ||
| Table | DRD | drdtab4 | 4 | Number of drug-induced deaths recorded in EU Member States according to EMCDDA standard definition 'Selection D', 1995 to 2010 | /stats12/drdtab4 | drdtab4 | Table-DRD-04-part0.xml | ||
| Table | DRD | drdtab5 | 5 | i | Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) | Population mortality rates, 2010 or last year with available information | /stats12/drdtab5a | drdtab5a | Table-DRD-05-parti.xml |
| Table | DRD | drdtab5 | 5 | ii | Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) | Proportional mortality due to drug-induced deaths, 2009 or last year with available information. | /stats12/drdtab5b | drdtab5b | Table-DRD-05-partii.xml |
| Table | DRD | drdtab5 | 5 | iii | Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) | Estimated mortality (numbers and population rates) due to AIDS attributable to injection drug use | /stats12/drdtab5c | drdtab5c | Table-DRD-05-partiii.xml |
| Table | DRD | drdtab106 | 106 | Methodological features of drug-induced deaths reported by National Reitox Focal Points (Based on national definitions - Reitox Standard Table 5) | /stats12/drdtab106 | drdtab106 | Table-DRD-106-part0.xml | ||
| Table | DRD | drdtab107 | 107 | i | Number of drug-induced deaths recorded in EU Member States according to national definitions | Total drug-induced deaths, 1985 to 2010 | /stats12/drdtab107a | drdtab107a | Table-DRD-107-parti.xml |
| Table | DRD | drdtab107 | 107 | ii | Number of drug-induced deaths recorded in EU Member States according to national definitions | Totals and indexes, 1985 to 2010 | /stats12/drdtab107b | drdtab107b | Table-DRD-107-partii.xml |
| Table | DRD | drdtab108 | 108 | Drug-induced deaths: Detailed qualitative national information on deaths due to specific substances in EU Member States (2011 National Reports) | /stats12/drdtab108 | drdtab108 | Table-DRD-108-part0.xml | ||
| Figure | DRD | drdfig1 | 1 | Proportion of drug-induced deaths that show presence of opioids for the most recent year reported | /stats12/drdfig1 | drdfig1 | Table-DRD-g01-part0.xml | ||
| Figure | DRD | drdfig2 | 2 | Proportion of drug-induced deaths occurring under the age of 25 years for the most recent year reported | /stats12/drdfig2 | drdfig2 | Table-DRD-g02-part0.xml | ||
| Figure | DRD | drdfig3 | 3 | Trends in mean age of drug-induced deaths in some of the EU-15 Member States, 1990 to 2010 | /stats12/drdfig3 | drdfig3 | Table-DRD-g03-part0.xml | ||
| Figure | DRD | drdfig4 | 4 | Trends in mean age of drug-induced deaths in some new EU Member States, 1990 to 2010 | /stats12/drdfig4 | drdfig4 | Table-DRD-g04-part0.xml | ||
| Figure | DRD | drdfig5 | 5 | i | lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 | Indexed trend in the EU-15 Member States and Norway 1990–2009 | /stats12/drdfig5a | drdfig5a | Table-DRD-g05-parti.xml |
| Figure | DRD | drdfig5 | 5 | ii | lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 | Indexed trend in the new Member States, 1990–2009 | /stats12/drdfig5b | drdfig5b | Table-DRD-g05-partii.xml |
| Figure | DRD | drdfig6 | 6 | Indexed overall trends for males and females in drug-induced deaths in the EU-15 Member States and Norway, 1990 to 2009 | /stats12/drdfig6 | drdfig6 | Table-DRD-g06-part0.xml | ||
| Figure | DRD | drdfig7 | 7 | i | Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported | Mortality rates per million among all adults (15 to 64 years) due to drug-related deaths | /stats12/drdfig7a | drdfig7a | Table-DRD-g07-parti.xml |
| Figure | DRD | drdfig7 | 7 | ii | Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported | Mortality rates among all adults (15 to 64 years) due to drug-related deaths and estimated mortality rates due to HIV/AIDS attributable to injection drug use | /stats12/drdfig7b | drdfig7b | Table-DRD-g07-partii.xml |
| Figure | DRD | drdfig8 | 8 | Indexed long term trend in drug-induced deaths in the EU-15 Member States and Norway, 1985 to 2009 | /stats12/drdfig8 | drdfig8 | Table-DRD-g08-part0.xml | ||
| Figure | DRD | drdfig9 | 9 | i | Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average) | Some EU Member States and Norway, 1990 to 2010 | /stats12/drdfig9a | drdfig9a | Table-DRD-g09-parti.xml |
| Figure | DRD | drdfig9 | 9 | ii | Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average) | Some EU Member States, 1990 to 2010 | /stats12/drdfig9b | drdfig9b | Table-DRD-g09-partii.xml |
| Figure | DRD | drdfig9 | 9 | iii | Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average) | Some EU countries, 1990 to 2010 | /stats12/drdfig9c | drdfig9c | Table-DRD-g09-partiii.xml |
| Figure | DRD | drdfig10 | 10 | Mean age of drug-induced deaths in EU Member States, last year with available data | /stats12/drdfig10 | drdfig10 | Table-DRD-g10-part0.xml | ||
| Figure | DRD | drdfig11 | 11 | i | Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole | Index in some Member States, 1985 to 2010 | /stats12/drdfig11a | drdfig11a | Table-DRD-g11-parti.xml |
| Figure | DRD | drdfig11 | 11 | ii | Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole | Index in some Member States, 1985 to 2010 | /stats12/drdfig11b | drdfig11b | Table-DRD-g11-partii.xml |
| Figure | DRD | drdfig11 | 11 | iii | Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole | Index in some Member States, 1985 to 2010 | /stats12/drdfig11c | drdfig11c | Table-DRD-g11-partiii.xml |
| Figure | DRD | drdfig12 | 12 | i | Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway | Changes between 2000 and 2003 | /stats12/drdfig12a | drdfig12a | Table-DRD-g12-parti.xml |
| Figure | DRD | drdfig12 | 12 | ii | Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway | Changes between 2003 and 2009/10 | /stats12/drdfig12b | drdfig12b | Table-DRD-g12-partii.xml |
| Figure | DRD | drdfig13 | 13 | i | Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions. | EU-15 Member States and Norway 1990–2009 | /stats12/drdfig13a | drdfig13a | Table-DRD-g13-parti.xml |
| Figure | DRD | drdfig13 | 13 | ii | Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions. | New Member States, 1990–2009 | /stats12/drdfig13b | drdfig13b | Table-DRD-g13-partii.xml |
| Table | DUP | duptab0 | 0 | Prevalence of drug use among prisoners — Sources and bibliographic references | /stats12/duptab0 | duptab0 | Table-DUP-00-parti.xml | ||
| Table | DUP | duptab1 | 1 | Prevalence of lifetime drug use among prisoners, 2000–2010 | /stats12/duptab1 | duptab1 | Table-DUP-01-parti.xml | ||
| Table | DUP | duptab2 | 2 | Prevalence of lifetime injecting drug use among prisoners, 2000–2010 | /stats12/duptab2 | duptab2 | Table-DUP-02-parti.xml | ||
| Table | DUP | duptab3 | 3 | Prevalence of drug use within prison among prisoners, 2000–2010 | /stats12/duptab3 | duptab3 | Table-DUP-03-parti.xml | ||
| Table | DUP | duptab4 | 4 | Prevalence of injecting drug use within prison among prisoners, 2000–2010 | /stats12/duptab4 | duptab4 | Table-DUP-04-parti.xml | ||
| Table | DUP | duptab105 | 105 | Prevalence (percentage) of drug use among prisoners in EU member states and Norway - full listing of studies | /stats12/duptab105 | duptab105 | Table-DUP-105-part0.xml | ||
| Table | EYE | eyetab0 | 0 | School surveys: Sources | /stats12/eyetab0 | eyetab0 | Table-EYE-00-part0.xml | ||
| Table | EYE | eyetab08 | 08 | HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old | /stats12/eyetab08 | eyetab08 | Table-EYE-08-part0.xml | ||
| Table | EYE | eyetab9 | 9 | i | HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10) | All students | /stats12/eyetab9a | eyetab9a | Table-EYE-09-parti.xml |
| Table | EYE | eyetab9 | 9 | ii | HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10) | Males | /stats12/eyetab9b | eyetab9b | Table-EYE-09-partii.xml |
| Table | EYE | eyetab9 | 9 | iii | HBSC school surveys (2009/10) percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10) | Females | /stats12/eyetab9c | eyetab9c | Table-EYE-09-partiii.xml |
| Table | EYE | eyetab10 | 10 | Recent school surveys (2005-2011): percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years old | /stats12/eyetab10 | eyetab10 | Table-EYE-10-part0.xml | ||
| Table | EYE | eyetab11 | 11 | School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years | /stats12/eyetab11 | eyetab11 | Table-EYE-11-part0.xml | ||
| Table | EYE | eyetab20 | 20 | i | ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years | All students | /stats12/eyetab20a | eyetab20a | Table-EYE-20-parti.xml |
| Table | EYE | eyetab20 | 20 | ii | ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years | Males | /stats12/eyetab20b | eyetab20b | Table-EYE-20-partii.xml |
| Table | EYE | eyetab20 | 20 | iii | ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years | Females | /stats12/eyetab20c | eyetab20c | Table-EYE-20-partiii.xml |
| Table | EYE | eyetab21 | 21 | i | ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years | All students | /stats12/eyetab21a | eyetab21a | Table-EYE-21-parti.xml |
| Table | EYE | eyetab21 | 21 | ii | ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years | Males | /stats12/eyetab21b | eyetab21b | Table-EYE-21-partii.xml |
| Table | EYE | eyetab21 | 21 | iii | ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years | Females | /stats12/eyetab21c | eyetab21c | Table-EYE-21-partiii.xml |
| Table | EYE | eyetab22 | 22 | i | All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years | All students | /stats12/eyetab22a | eyetab22a | Table-EYE-22-parti.xml |
| Table | EYE | eyetab22 | 22 | ii | All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years | Males | /stats12/eyetab22b | eyetab22b | Table-EYE-22-partii.xml |
| Table | EYE | eyetab22 | 22 | iii | All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years | Females | /stats12/eyetab22c | eyetab22c | Table-EYE-22-partiii.xml |
| Table | EYE | eyetab23 | 23 | i | All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years | All students | /stats12/eyetab23a | eyetab23a | Table-EYE-23-parti.xml |
| Table | EYE | eyetab23 | 23 | ii | All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years | Males | /stats12/eyetab23b | eyetab23b | Table-EYE-23-partii.xml |
| Table | EYE | eyetab23 | 23 | iii | All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years | Females | /stats12/eyetab23c | eyetab23c | Table-EYE-23-partiii.xml |
| Table | EYE | eyetab30 | 30 | Recent School Surveys (2003-2011): percentage lifetime prevalence of psychoactive substance use and last month prevalence of cannabis among students aged 17-18 years old | /stats12/eyetab30 | eyetab30 | Table-EYE-30-part0.xml | ||
| Figure | EYE | eyefig1 | 1 | i | Cannabis prevalence rates, ESPAD 2011 | Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey | /stats12/eyefig1a | eyefig1a | Table-EYE-g01-parti.xml |
| Figure | EYE | eyefig1 | 1 | ii | Cannabis prevalence rates, ESPAD 2011 | Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey | /stats12/eyefig1b | eyefig1b | Table-EYE-g01-partii.xml |
| Figure | EYE | eyefig1 | 1 | iii | Cannabis prevalence rates, ESPAD 2011 | Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey | /stats12/eyefig1c | eyefig1c | Table-EYE-g01-partiii.xml |
| Figure | EYE | eyefig1 | 1 | iv | Cannabis prevalence rates, ESPAD 2011 | Comparison of lifetime prevalence of cannabis use with perceived great risk (percentages), among 15/16 year olds school students in 2007/2011 | /stats12/eyefig1d | eyefig1d | Table-EYE-g01-partiv.xml |
| Table | GPS | gpstab0 | 0 | Nationwide surveys among the general population: Bibliographic references | /stats12/gpstab0 | gpstab0 | Table-GPS-00-part0.xml | ||
| Table | GPS | gpstab1 | 1 | i | Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000. | Survey methods. | /stats12/gpstab1a | gpstab1a | Table-GPS-01-parti.xml |
| Table | GPS | gpstab1 | 1 | ii | Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000. | All adults (aged 15 - 64). | /stats12/gpstab1b | gpstab1b | Table-GPS-01-partii.xml |
| Table | GPS | gpstab1 | 1 | iii | Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000. | Young adults (aged 15 - 34). | /stats12/gpstab1c | gpstab1c | Table-GPS-01-partiii.xml |
| Table | GPS | gpstab1 | 1 | iv | Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000. | Youth (15 - 24). | /stats12/gpstab1d | gpstab1d | Table-GPS-01-partiv.xml |
| Table | GPS | gpstab2 | 2 | i | Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000. | All adults (aged 15 - 64). | /stats12/gpstab2a | gpstab2a | Table-GPS-02-parti.xml |
| Table | GPS | gpstab2 | 2 | ii | Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000. | Young adults (15 - 34). | /stats12/gpstab2b | gpstab2b | Table-GPS-02-partii.xml |
| Table | GPS | gpstab2 | 2 | iii | Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000. | Youth (aged 15 - 24). | /stats12/gpstab2c | gpstab2c | Table-GPS-02-partiii.xml |
| Table | GPS | gpstab3 | 3 | i | Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000. | All adults (aged 15 - 64). | /stats12/gpstab3a | gpstab3a | Table-GPS-03-parti.xml |
| Table | GPS | gpstab3 | 3 | ii | Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000. | Young adults (15 - 34). | /stats12/gpstab3b | gpstab3b | Table-GPS-03-partii.xml |
| Table | GPS | gpstab3 | 3 | iii | Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000. | Youth (aged 15 - 24). | /stats12/gpstab3c | gpstab3c | Table-GPS-03-partiii.xml |
| Table | GPS | gpstab4 | 4 | i | Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | All adults male (aged 15 - 64). | /stats12/gpstab4a | gpstab4a | Table-GPS-04-parti.xml |
| Table | GPS | gpstab4 | 4 | ii | Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | All adults female (aged 15 - 64). | /stats12/gpstab4b | gpstab4b | Table-GPS-04-partii.xml |
| Table | GPS | gpstab4 | 4 | iii | Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Young adults male (aged 15 - 34). | /stats12/gpstab4c | gpstab4c | Table-GPS-04-partiii.xml |
| Table | GPS | gpstab4 | 4 | iv | Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Young adults female (aged 15 - 34). | /stats12/gpstab4d | gpstab4d | Table-GPS-04-partiv.xml |
| Table | GPS | gpstab4 | 4 | v | Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Youth male (aged 15 - 24). | /stats12/gpstab4e | gpstab4e | Table-GPS-04-partv.xml |
| Table | GPS | gpstab4 | 4 | vi | Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Youth female (aged 15 - 24). | /stats12/gpstab4f | gpstab4f | Table-GPS-04-partvi.xml |
| Table | GPS | gpstab5 | 5 | i | Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | All adults male (aged 15 - 64). | /stats12/gpstab5a | gpstab5a | Table-GPS-05-parti.xml |
| Table | GPS | gpstab5 | 5 | ii | Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | All adults female (aged 15 - 64). | /stats12/gpstab5b | gpstab5b | Table-GPS-05-partii.xml |
| Table | GPS | gpstab5 | 5 | iii | Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Young adults male (aged 15 - 34). | /stats12/gpstab5c | gpstab5c | Table-GPS-05-partiii.xml |
| Table | GPS | gpstab5 | 5 | iv | Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Young adults female (aged 15 - 34). | /stats12/gpstab5d | gpstab5d | Table-GPS-05-partiv.xml |
| Table | GPS | gpstab5 | 5 | v | Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Youth male (aged 15 - 24). | /stats12/gpstab5e | gpstab5e | Table-GPS-05-partv.xml |
| Table | GPS | gpstab5 | 5 | vi | Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Youth female (aged 15 - 24). | /stats12/gpstab5f | gpstab5f | Table-GPS-05-partvi.xml |
| Table | GPS | gpstab6 | 6 | i | Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | All adults male (aged 15 - 64). | /stats12/gpstab6a | gpstab6a | Table-GPS-06-parti.xml |
| Table | GPS | gpstab6 | 6 | ii | Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | All adults female (aged 15 - 64). | /stats12/gpstab6b | gpstab6b | Table-GPS-06-partii.xml |
| Table | GPS | gpstab6 | 6 | iii | Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Young adults male (aged 15 - 34). | /stats12/gpstab6c | gpstab6c | Table-GPS-06-partiii.xml |
| Table | GPS | gpstab6 | 6 | iv | Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Young adults female (aged 15 - 34). | /stats12/gpstab6d | gpstab6d | Table-GPS-06-partiv.xml |
| Table | GPS | gpstab6 | 6 | v | Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Youth male (aged 15 - 24). | /stats12/gpstab6e | gpstab6e | Table-GPS-06-partv.xml |
| Table | GPS | gpstab6 | 6 | vi | Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. | Youth female (aged 15 - 24). | /stats12/gpstab6f | gpstab6f | Table-GPS-06-partvi.xml |
| Table | GPS | gpstab7 | 7 | i | Lifetime prevalence of drug use in all available national general population surveys. | Survey methods. | /stats12/gpstab7a | gpstab7a | Table-GPS-07-parti.xml |
| Table | GPS | gpstab7 | 7 | ii | Lifetime prevalence of drug use in all available national general population surveys. | All adults (aged 15 -64). | /stats12/gpstab7b | gpstab7b | Table-GPS-07-partii.xml |
| Table | GPS | gpstab7 | 7 | iii | Lifetime prevalence of drug use in all available national general population surveys. | Young adults (aged 15 -34). | /stats12/gpstab7c | gpstab7c | Table-GPS-07-partiii.xml |
| Table | GPS | gpstab7 | 7 | iv | Lifetime prevalence of drug use in all available national general population surveys. | Youth (aged 15 - 24). | /stats12/gpstab7d | gpstab7d | Table-GPS-07-partiv.xml |
| Table | GPS | gpstab8 | 8 | i | Last 12 months prevalence of drug use in all available national general population surveys. | All adults (aged 15 - 64). | /stats12/gpstab8a | gpstab8a | Table-GPS-08-parti.xml |
| Table | GPS | gpstab8 | 8 | ii | Last 12 months prevalence of drug use in all available national general population surveys. | Young adults (15 - 34). | /stats12/gpstab8b | gpstab8b | Table-GPS-08-partii.xml |
| Table | GPS | gpstab8 | 8 | iii | Last 12 months prevalence of drug use in all available national general population surveys. | Youth (aged 15 - 24). | /stats12/gpstab8c | gpstab8c | Table-GPS-08-partiii.xml |
| Table | GPS | gpstab9 | 9 | i | Last 30 days prevalence of drug use in all available national general population surveys. | All adults (aged 15 - 64). | /stats12/gpstab9a | gpstab9a | Table-GPS-09-parti.xml |
| Table | GPS | gpstab9 | 9 | ii | Last 30 days prevalence of drug use in all available national general population surveys. | Young adults (15 - 34). | /stats12/gpstab9b | gpstab9b | Table-GPS-09-partii.xml |
| Table | GPS | gpstab9 | 9 | iii | Last 30 days prevalence of drug use in all available national general population surveys. | Youth (aged 15 - 24). | /stats12/gpstab9c | gpstab9c | Table-GPS-09-partiii.xml |
| Table | GPS | gpstab10 | 10 | i | Frequency of use of cannabis amongst users in the last 30 days in national general population surveys. | All adults (aged 15 - 64) - most recent data. | /stats12/gpstab10a | gpstab10a | Table-GPS-10-parti.xml |
| Table | GPS | gpstab10 | 10 | ii | Frequency of use of cannabis amongst users in the last 30 days in national general population surveys. | All adults (aged 15 - 64) - 2007 field trial. | /stats12/gpstab10b | gpstab10b | Table-GPS-10-partii.xml |
| Table | GPS | gpstab10 | 10 | iii | Frequency of use of cannabis amongst users in the last 30 days in national general population surveys. | All adults (aged 15 - 64) - 2004 field trial. | /stats12/gpstab10c | gpstab10c | Table-GPS-10-partiii.xml |
| Table | GPS | gpstab10 | 10 | iv | Frequency of use of cannabis amongst users in the last 30 days in national general population surveys. | Young adults (aged 15 - 34) - combined sources. | /stats12/gpstab10d | gpstab10d | Table-GPS-10-partiv.xml |
| Table | GPS | gpstab121 | 121 | Methodological information for nation-wide surveys among the general population | /stats12/gpstab121 | gpstab121 | Table-GPS-121-part0.xml | ||
| Figure | GPS | gpsfig1 | 1 | Last 12 months prevalence of cannabis use among all adults (aged 15 - 64), young adults (aged 15 - 34) and for youth (aged 15 - 24) | /stats12/gpsfig1 | gpsfig1 | Table-GPS-g01-part0.xml | ||
| Figure | GPS | gpsfig2 | 2 | Continuation rates of cannabis use (last 12 months use and last 30 days use as proportions of lifetime use) | /stats12/gpsfig2 | gpsfig2 | Table-GPS-g02-part0.xml | ||
| Figure | GPS | gpsfig3 | 3 | Last 30 days prevalence of cannabis use among youth (aged 15 - 24) | /stats12/gpsfig3 | gpsfig3 | Table-GPS-g03-part0.xml | ||
| Figure | GPS | gpsfig4 | 4 | i | Trends in last 12 months prevalence of cannabis use among young adults (aged 15 - 34) | All countries | /stats12/gpsfig4a | gpsfig4a | Table-GPS-g04-parti.xml |
| Figure | GPS | gpsfig4 | 4 | ii | Trends in last 12 months prevalence of cannabis use among young adults (aged 15 - 34) | Countries with three or more surveys | /stats12/gpsfig4b | gpsfig4b | Table-GPS-g04-partii.xml |
| Figure | GPS | gpsfig5 | 5 | Last 12 months prevalence of amphetamines use among young adults (aged 15 - 34) and youth (aged 15 - 24) | /stats12/gpsfig5 | gpsfig5 | Table-GPS-g05-part0.xml | ||
| Figure | GPS | gpsfig6 | 6 | Last 12 months prevalence of amphetamines use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24) | /stats12/gpsfig6 | gpsfig6 | Table-GPS-g06-part0.xml | ||
| Figure | GPS | gpsfig7 | 7 | Last 30 days prevalence of cannabis use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24) | /stats12/gpsfig7 | gpsfig7 | Table-GPS-g07-part0.xml | ||
| Figure | GPS | gpsfig8 | 8 | i | Trends in last 12 months use of amphetamines among young adults (aged 15 - 34) | All countries | /stats12/gpsfig8a | gpsfig8a | Table-GPS-g08-parti.xml |
| Figure | GPS | gpsfig8 | 8 | ii | Trends in last 12 months use of amphetamines among young adults (aged 15 - 34) | Countries with three or more surveys | /stats12/gpsfig8b | gpsfig8b | Table-GPS-g08-partii.xml |
| Figure | GPS | gpsfig9 | 9 | i | Last 12 months prevalence of ecstasy use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24) | All age groups | /stats12/gpsfig9a | gpsfig9a | Table-GPS-g09-parti.xml |
| Figure | GPS | gpsfig9 | 9 | ii | Last 12 months prevalence of ecstasy use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24) | Males aged 15 to 24 in countries with high prevalence rates | /stats12/gpsfig9b | gpsfig9b | Table-GPS-g09-partii.xml |
| Figure | GPS | gpsfig10 | 10 | Last 12 months prevalence of cannabis use by age group in United Kingdom (E&W) | /stats12/gpsfig10 | gpsfig10 | Table-GPS-g10-part0.xml | ||
| Figure | GPS | gpsfig11 | 11 | Continuation rates of ecstasy use (last 12 months use and last 30 days use as proportions of lifetime use) | /stats12/gpsfig11 | gpsfig11 | Table-GPS-g11-part0.xml | ||
| Figure | GPS | gpsfig12 | 12 | i | Last 12 months prevalence of cannabis use by age group | Selected EU-15 countries | /stats12/gpsfig12a | gpsfig12a | Table-GPS-g12-parti.xml |
| Figure | GPS | gpsfig12 | 12 | ii | Last 12 months prevalence of cannabis use by age group | Selected 'new' EU countries | /stats12/gpsfig12b | gpsfig12b | Table-GPS-g12-partii.xml |
| Figure | GPS | gpsfig13 | 13 | Last 12 months prevalence of cocaine use among young adults (aged 15 - 34) by gender | /stats12/gpsfig13 | gpsfig13 | Table-GPS-g13-part0.xml | ||
| Figure | GPS | gpsfig14 | 14 | i | Trends in last 12 months prevalence of cocaine use among young adults (aged 15 - 34) | All countries | /stats12/gpsfig14a | gpsfig14a | Table-GPS-g14-parti.xml |
| Figure | GPS | gpsfig14 | 14 | ii | Trends in last 12 months prevalence of cocaine use among young adults (aged 15 - 34) | Countries with three or more surveys | /stats12/gpsfig14b | gpsfig14b | Table-GPS-g14-partii.xml |
| Figure | GPS | gpsfig15 | 15 | Last 12 months prevalence of cocaine use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24) | /stats12/gpsfig15 | gpsfig15 | Table-GPS-g15-part0.xml | ||
| Figure | GPS | gpsfig16 | 16 | Continuation rates of cocaine use (last 12 months use and last 30 days use as proportions of lifetime use) | /stats12/gpsfig16 | gpsfig16 | Table-GPS-g16-part0.xml | ||
| Figure | GPS | gpsfig17 | 17 | Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) | /stats12/gpsfig17 | gpsfig17 | Table-GPS-g17-part0.xml | ||
| Figure | GPS | gpsfig18 | 18 | i | Overview of drug prevalence estimates in Europe for all adults (aged 15 - 64) and young adults (aged 15 - 34) | Cannabis use – lifetime experience, last 12 months and last 30 days prevalence | /stats12/gpsfig18a | gpsfig18a | Table-GPS-g18-parti.xml |
| Figure | GPS | gpsfig18 | 18 | ii | Overview of drug prevalence estimates in Europe for all adults (aged 15 - 64) and young adults (aged 15 - 34) | Cocaine, amphetamines and ecstasy use – lifetime experience, last 12 months and last 30 days prevalence | /stats12/gpsfig18b | gpsfig18b | Table-GPS-g18-partii.xml |
| Figure | GPS | gpsfig20 | 20 | Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15 - 34) in Europe, Canada, Australia and the USA | /stats12/gpsfig20 | gpsfig20 | Table-GPS-g20-part0.xml | ||
| Figure | GPS | gpsfig21 | 21 | i | Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 - 34) | All countries | /stats12/gpsfig21a | gpsfig21a | Table-GPS-g21-parti.xml |
| Figure | GPS | gpsfig21 | 21 | ii | Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 - 34) | Countries with three or more surveys | /stats12/gpsfig21b | gpsfig21b | Table-GPS-g21-partii.xml |
| Figure | GPS | gpsfig22 | 22 | Continuation rates of amphetamine use (last 12 months use and last 30 days use as proportions of lifetime use) | /stats12/gpsfig22 | gpsfig22 | Table-GPS-g22-part0.xml | ||
| Figure | GPS | gpsfig23 | 23 | i | Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) | United Kingdom (E&W) | /stats12/gpsfig23a | gpsfig23a | Table-GPS-g23-parti.xml |
| Figure | GPS | gpsfig23 | 23 | ii | Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) | Denmark | /stats12/gpsfig23b | gpsfig23b | Table-GPS-g23-partii.xml |
| Figure | GPS | gpsfig23 | 23 | iii | Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) | Germany | /stats12/gpsfig23c | gpsfig23c | Table-GPS-g23-partiii.xml |
| Figure | GPS | gpsfig23 | 23 | iv | Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) | Spain | /stats12/gpsfig23d | gpsfig23d | Table-GPS-g23-partiv.xml |
| Figure | GPS | gpsfig23 | 23 | v | Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) | France | /stats12/gpsfig23e | gpsfig23e | Table-GPS-g23-partv.xml |
| Table | HSR | hsrtab1 | 1 | Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/naloxone combination, heroin-assisted treatment and slow-release morphine | /stats12/hsrtab1 | hsrtab1 | Table-HSR-01-part0.xml | ||
| Table | HSR | hsrtab2 | 2 | i | Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway | Legal framework regarding the initiation of OST by substitution medication | /stats12/hsrtab2a | hsrtab2a | Table-HSR-02-parti.xml |
| Table | HSR | hsrtab2 | 2 | ii | Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway | Legal framework regarding the continuation of OST by substitution medication | /stats12/hsrtab2b | hsrtab2b | Table-HSR-02-partii.xml |
| Table | HSR | hsrtab2 | 2 | iii | Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway | Legal framework regarding the dispensing of substitution medications | /stats12/hsrtab2c | hsrtab2c | Table-HSR-02-partiii.xml |
| Table | HSR | hsrtab3 | 3 | i | Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) | Estimates of clients in methadone treatment or any opioid substitution in EU-27, Croatia, Turkey and Norway, 1993 - 2010 | /stats12/hsrtab3a | hsrtab3a | Table-HSR-03-parti.xml |
| Table | HSR | hsrtab3 | 3 | ii | Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) | Estimates and share of clients in methadone (MMT) and buprenorphine-based opioid substitution treatment in EU-27, Croatia, Turkey and Norway in 2010 or latest available year | /stats12/hsrtab3b | hsrtab3b | Table-HSR-03-partii.xml |
| Table | HSR | hsrtab3 | 3 | iii | Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) | Methodological notes EU-27, Croatia, Turkey and Norway, 2003 - 2010 | /stats12/hsrtab3c | hsrtab3c | Table-HSR-03-partiii.xml |
| Table | HSR | hsrtab4 | 4 | i | Needle and syringe programmes (NSPs) | Year of introduction of needle and syringe programmes (NSPs), types of programmes available in 2010 and number of sites | /stats12/hsrtab4a | hsrtab4a | Table-HSR-04-parti.xml |
| Table | HSR | hsrtab4 | 4 | ii | Needle and syringe programmes (NSPs) | NSP geographical coverage, 2010 or latest available year | /stats12/hsrtab4b | hsrtab4b | Table-HSR-04-partii.xml |
| Table | HSR | hsrtab5 | 5 | i | Provision of needle and syringe programmes (NSPs) | Syringes provided through needle and syringe programmes (NSPs), 2003-2010 | /stats12/hsrtab5a | hsrtab5a | Table-HSR-05-parti.xml |
| Table | HSR | hsrtab5 | 5 | ii | Provision of needle and syringe programmes (NSPs) | Clients and contacts at specialist NSP agencies, 2009-2010 | /stats12/hsrtab5b | hsrtab5b | Table-HSR-05-partii.xml |
| Table | HSR | hsrtab6 | 6 | i | Hepatitis responses in Europe | Hepatitis B immunization in EU27, Croatia, Turkey and Norway | /stats12/hsrtab6a | hsrtab6a | Table-HSR-06-parti.xml |
| Table | HSR | hsrtab6 | 6 | ii | Hepatitis responses | Availability of Hepatitis C testing in EU27, Croatia, Turkey and Norway | /stats12/hsrtab6b | hsrtab6b | Table-HSR-06-partii.xml |
| Table | HSR | hsrtab7 | 7 | Availability of selected health responses in prison in EU-27, Croatia, Turkey and Norway | /stats12/hsrtab7 | hsrtab7 | Table-HSR-07-part0.xml | ||
| Table | HSR | hsrtab8 | 8 | i | Responses to drug related deaths in Europe | Availability of selected responses to reduce drug related deaths in 27 EU countries, Norway and Turkey (expert ratings) | /stats12/hsrtab8a | hsrtab8a | Table-HSR-08-parti.xml |
| Table | HSR | hsrtab8 | 8 | ii | Responses to drug related deaths in Europe | Availability of information material on drug-related deaths and emergencies for specific target groups in 27 EU countries, Norway and Turkey | /stats12/hsrtab8b | hsrtab8b | Table-HSR-08-partii.xml |
| Table | HSR | hsrtab9 | 9 | Opioid substitution treatment in prison in EU 27, Croatia, Turkey and Norway | /stats12/hsrtab9 | hsrtab9 | Table-HSR-09-part0.xml | ||
| Table | HSR | hsrtab10 | 10 | Estimation of the total number of clients in treatment in 2010 or latest available year | /stats12/hsrtab10 | hsrtab10 | Table-HSR-10-part0.xml | ||
| Figure | HSR | hsrfig1 | 1 | i | Opioid substitution treatment coverage | Opioid substitution treatment clients as a percentage of the estimated number of problem opioid users, 2010 or most recent year available | /stats12/hsrfig1a | hsrfig1a | Table-HSR-g01-parti.xml |
| Figure | HSR | hsrfig1 | 1 | ii | Opioid substitution treatment coverage | Overall estimated number of problem opioid users in treatment (in opioid substitution treatment and other treatments) as a percentage of the estimated number of problem opioid users, 2010 or most recent year available | /stats12/hsrfig1b | hsrfig1b | Table-HSR-g01-partii.xml |
| Figure | HSR | hsrfig2 | 2 | Estimated number of clients in opioid substitution treatment (OST) in EU15-12, 1993 - 2010. | /stats12/hsrfig2 | hsrfig2 | Table-HSR-g02-part0.xml | ||
| Figure | HSR | hsrfig3 | 3 | Syringes distributed through specialised programmes in 2010 per estimated IDU | /stats12/hsrfig3 | hsrfig3 | Table-HSR-g03-part0.xml | ||
| Figure | HSR | hsrfig4 | 4 | Proportion of prison population receiving opioid substitution treatment (OST) on a given day in 2010 or latest available year | /stats12/hsrfig4 | hsrfig4 | Table-HSR-g04-part0.xml | ||
| Table | INF | inftab0 | 0 | Bibliographic references | /stats12/inftab0 | inftab0 | Table-INF-00-part0.xml | ||
| Table | INF | inftab1 | 1 | Prevalence of HIV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country | /stats12/inftab1 | inftab1 | Table-INF-01-part0.xml | ||
| Table | INF | inftab2 | 2 | Prevalence of HCV antibody among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country | /stats12/inftab2 | inftab2 | Table-INF-02-part0.xml | ||
| Table | INF | inftab3 | 3 | Prevalence of markers for HBV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country | /stats12/inftab3 | inftab3 | Table-INF-03-part0.xml | ||
| Table | INF | inftab104 | 104 | i | HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis | HIV infection in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes | /stats12/inftab104a | inftab104a | Table-INF-104-parti.xml |
| Table | INF | inftab104 | 104 | ii | HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis | HIV infection in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes | /stats12/inftab104b | inftab104b | Table-INF-104-partii.xml |
| Table | INF | inftab104 | 104 | iii | HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis | AIDS incidence in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes | /stats12/inftab104c | inftab104c | Table-INF-104-partiii.xml |
| Table | INF | inftab104 | 104 | iv | HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis | AIDS incidence in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes | /stats12/inftab104d | inftab104d | Table-INF-104-partiv.xml |
| Table | INF | inftab105 | 105 | i | Notified cases of hepatitis C infection among injecting drug users in the EU countries, Croatia and Norway | Total number of cases where transmission route known, number of IDU cases, and percentage of IDUs amongst all cases with known risk factor | /stats12/inftab105a | inftab105a | Table-INF-105-parti.xml |
| Table | INF | inftab105 | 105 | ii | Notified cases of hepatitis C infection among injecting drug users in the EU countries, Croatia and Norway | Case definitions | /stats12/inftab105b | inftab105b | Table-INF-105-partii.xml |
| Table | INF | inftab106 | 106 | i | Notified cases of hepatitis B infection among injecting drug users in the EU countries, Croatia and Norway | Total number of cases where transmission route known, number of IDU cases, and percentage of IDUs amongst all cases with known risk factor | /stats12/inftab106a | inftab106a | Table-INF-106-parti.xml |
| Table | INF | inftab106 | 106 | ii | Notified cases of hepatitis B infection among injecting drug users in the EU countries, Croatia and Norway | Case definitions | /stats12/inftab106b | inftab106b | Table-INF-106-partii.xml |
| Table | INF | inftab108 | 108 | Prevalence of HIV infection among injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway | /stats12/inftab108 | inftab108 | Table-INF-108-part0.xml | ||
| Table | INF | inftab109 | 109 | Prevalence of HIV infection among injecting drug users under age 25 (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway | /stats12/inftab109 | inftab109 | Table-INF-109-part0.xml | ||
| Table | INF | inftab110 | 110 | Prevalence of HIV infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway | /stats12/inftab110 | inftab110 | Table-INF-110-part0.xml | ||
| Table | INF | inftab111 | 111 | Prevalence of hepatitis C infection among injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway | /stats12/inftab111 | inftab111 | Table-INF-111-part0.xml | ||
| Table | INF | inftab112 | 112 | Prevalence of hepatitis C infection among injecting drug users under age 25 (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway | /stats12/inftab112 | inftab112 | Table-INF-112-part0.xml | ||
| Table | INF | inftab113 | 113 | Prevalence of hepatitis C infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway | /stats12/inftab113 | inftab113 | Table-INF-113-part0.xml | ||
| Table | INF | inftab114 | 114 | Prevalence of current hepatitis B infection among injecting drug users (% with HBsAg), 1991 to 2010. EU countries, Croatia, Turkey and Norway | /stats12/inftab114 | inftab114 | Table-INF-114-part0.xml | ||
| Table | INF | inftab115 | 115 | Prevalence of antibodies against hepatitis B virus among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway | /stats12/inftab115 | inftab115 | Table-INF-115-part0.xml | ||
| Figure | INF | inffig1 | 1 | i | AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998 to 2010 | EU countries, Croatia, Turkey and Norway | /stats12/inffig1a | inffig1a | Table-INF-g01-parti.xml |
| Figure | INF | inffig1 | 1 | ii | AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998 to 2010 | Non-EU countries of the WHO European region | /stats12/inffig1b | inffig1b | Table-INF-g01-partii.xml |
| Figure | INF | inffig2 | 2 | i | HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010. | EU countries, Croatia, Turkey and Norway: five highest countries in peak value 2005-2010 | /stats12/inffig2a | inffig2a | Table-INF-g02-parti.xml |
| Figure | INF | inffig2 | 2 | ii | HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010. | EU countries, Croatia, Turkey and Norway: countries with 5 to 10 cases per million population in peak value 2005-2010 | /stats12/inffig2b | inffig2b | Table-INF-g02-partii.xml |
| Figure | INF | inffig2 | 2 | iii | HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010. | Non-EU countries of WHO European region with over 50 cases per million population in peak value 2005-2010 | /stats12/inffig2c | inffig2c | Table-INF-g02-partiii.xml |
| Figure | INF | inffig2 | 2 | iv | HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010. | Non-EU countries of WHO European region with 10 to 50 cases per million population in peak value 2005-2010 | /stats12/inffig2d | inffig2d | Table-INF-g02-partiv.xml |
| Figure | INF | inffig3 | 3 | i | HIV prevalence among injecting drug users — studies with national and subnational coverage | All injecting drug users, 2009 to 2010 | /stats12/inffig3a | inffig3a | Table-DRD-g03-partii.xml |
| Figure | INF | inffig3 | 3 | ii | HIV prevalence among injecting drug users — studies with national and subnational coverage | Young injecting drug users (under age 25), 2009 to 2010 | /stats12/inffig3b | inffig3b | Table-DRD-g03-partii.xml |
| Figure | INF | inffig3 | 3 | iii | HIV prevalence among injecting drug users — studies with national and subnational coverage | New injecting drug users (injecting less than 2 years), 2009 to 2010 | /stats12/inffig3c | inffig3c | Table-DRD-g03-partii.xml |
| Figure | INF | inffig6 | 6 | i | HCV antibody prevalence among injecting drug users - studies with national and subnational coverage | All injecting drug users, 2009 to 2010 | /stats12/inffig6a | inffig6a | Table-INF-g06-parti.xml |
| Figure | INF | inffig6 | 6 | ii | HCV antibody prevalence among injecting drug users - studies with national and subnational coverage | Young injecting drug users (under age 25), 2009 to 2010 | /stats12/inffig6b | inffig6b | Table-INF-g06-parti.xml |
| Figure | INF | inffig6 | 6 | iii | HCV antibody prevalence among injecting drug users - studies with national and subnational coverage | New injecting drug users (injecting less than 2 years), 2009 to 2010 | /stats12/inffig6c | inffig6c | Table-INF-g06-parti.xml |
| Figure | INF | inffig9 | 9 | i | Prevalence of markers of HBV infection among injecting drug users — studies with national and subnational coverage | Percentage ever infected (positive for aHBc), 2009 to 2010 | /stats12/inffig9a | inffig9a | Table-INF-g09-parti.xml |
| Figure | INF | inffig9 | 9 | ii | Prevalence of markers of HBV infection among injecting drug users - studies with national and subnational coverage | Percentage with current infection (positive for HBsAg), 2009 to 2010 | /stats12/inffig9b | inffig9b | Table-INF-g09-partii.xml |
| Table | PDU | pdutab0 | 0 | Estimates of prevalence of problem drug use at national and subnational level: bibliographic references | /stats12/pdutab0 | pdutab0 | Table-PDU-00-part0.xml | ||
| Table | PDU | pdutab1 | 1 | i | Estimates of prevalence of problem drug use at national level: Summary Table, 2005–2010, rate per 1000 aged 15–64 | Overall problem drug use | /stats12/pdutab1a | pdutab1a | Table-PDU-01-parti.xml |
| Table | PDU | pdutab1 | 1 | ii | Estimates of prevalence of problem drug use at national level: Summary Table, 2005-2010, rate per 1000 aged 15–64 | Injecting drug use | /stats12/pdutab1b | pdutab1b | Table-PDU-01-partii.xml |
| Table | PDU | pdutab1 | 1 | iii | Estimates of prevalence of problem drug use at national level: Summary Table, 2005-2010, rate per 1000 aged 15-64 | Problem opioid use | /stats12/pdutab1c | pdutab1c | Table-PDU-01-partiii.xml |
| Table | PDU | pdutab6 | 6 | i | Estimated trends in the prevalence of problem and injecting drug use - 2005 to 2010 (rate per 1 000 population aged 15 to 64): Combined estimates per country | Estimated trends of overall problem drug use | /stats12/pdutab6a | pdutab6a | Table-PDU-06-parti.xml |
| Table | PDU | pdutab6 | 6 | ii | Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1 000 population aged 15 to 64): Combined estimates per country | Estimated trends of problem opioid use | /stats12/pdutab6b | pdutab6b | Table-PDU-06-partii.xml |
| Table | PDU | pdutab6 | 6 | iii | Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1000 population aged 15 to 64): Combined estimates per country | Estimated trends of injecting drug use | /stats12/pdutab6c | pdutab6c | Table-PDU-06-partiii.xml |
| Table | PDU | pdutab6 | 6 | iv | Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1000 population aged 15 to 64): Combined estimates per country | Estimated trends of problem stimulant use | /stats12/pdutab6d | pdutab6d | Table-PDU-06-partiv.xml |
| Table | PDU | pdutab102 | 102 | i | Prevalence of problem drug use at national level - full listing of studies | Problem drug use | /stats12/pdutab102a | pdutab102a | Table-PDU-102-parti.xml |
| Table | PDU | pdutab102 | 102 | ii | Prevalence of problem drug use at national level - full listing of studies | Injecting drug use | /stats12/pdutab102b | pdutab102b | Table-PDU-102-partii.xml |
| Table | PDU | pdutab103 | 103 | i | Prevalence of problem drug use at subnational level - full list of studies | Problem drug users | /stats12/pdutab103a | pdutab103a | Table-PDU-103-parti.xml |
| Table | PDU | pdutab103 | 103 | ii | Prevalence of problem drug use at subnational level - full list of studies | Injecting drug users | /stats12/pdutab103b | pdutab103b | Table-PDU-103-partii.xml |
| Table | PDU | pdutab104 | 104 | Trends in injecting drug use - percentage currently injecting among all clients entering treatment for primary drug heroin, 2005 to 2010 | /stats12/pdutab104 | pdutab104 | Table-PDU-104-part0.xml | ||
| Figure | PDU | pdufig1 | 1 | i | Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2005 to 2010 - last study available | Estimates of overall problem drug use | /stats12/pdufig1a | pdufig1a | Table-PDU-g01-parti.xml |
| Figure | PDU | pdufig1 | 1 | ii | Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), 2005 to 2010 — last study available | Estimates of problem opioid use | /stats12/pdufig1b | pdufig1b | Table-PDU-g01-partii.xml |
| Figure | PDU | pdufig2 | 2 | Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), 2005 to 2010 — last study available | /stats12/pdufig2 | pdufig2 | Table-PDU-g02-part0.xml | ||
| Table | PPP | ppptab1 | 1 | i | Price of cannabis products at retail level, 2010 | Minimum, maximum, mean, median and modal price in euros | /stats12/ppptab1a | ppptab1a | Table-PPP-01-parti.xml |
| Table | PPP | ppptab1 | 1 | ii | Price of cannabis products at retail level, 2010 | Sources of information | /stats12/ppptab1b | ppptab1b | Table-PPP-01-partii.xml |
| Table | PPP | ppptab1 | 1 | iii | Price of cannabis products at retail level, 2010 | Geographical coverage / Methodology | /stats12/ppptab1c | ppptab1c | Table-PPP-01-partiii.xml |
| Table | PPP | ppptab2 | 2 | i | Price of heroin at retail level, 2010 | Minimum, maximum, mean, median and modal price in euros | /stats12/ppptab2a | ppptab2a | Table-PPP-02-parti.xml |
| Table | PPP | ppptab2 | 2 | ii | Price of heroin at retail level, 2010 | Sources of information | /stats12/ppptab2b | ppptab2b | Table-PPP-02-partii.xml |
| Table | PPP | ppptab2 | 2 | iii | Price of heroin at retail level, 2010 | Geographical coverage / Methodology | /stats12/ppptab2c | ppptab2c | Table-PPP-02-partiii.xml |
| Table | PPP | ppptab3 | 3 | i | Price of cocaine products at retail level, 2010 | Minimum, maximum, mean, median and modal price in euros | /stats12/ppptab3a | ppptab3a | Table-PPP-03-parti.xml |
| Table | PPP | ppptab3 | 3 | ii | Price of cocaine products at retail level, 2010 | Sources of information | /stats12/ppptab3b | ppptab3b | Table-PPP-03-partii.xml |
| Table | PPP | ppptab3 | 3 | iii | Price of cocaine products at retail level, 2010 | Geographical coverage / Methodology | /stats12/ppptab3c | ppptab3c | Table-PPP-03-partiii.xml |
| Table | PPP | ppptab4 | 4 | i | Price of synthetic drugs at retail level, 2010 | Minimum, maximum, mean, median and modal price in euros | /stats12/ppptab4a | ppptab4a | Table-PPP-04-parti.xml |
| Table | PPP | ppptab4 | 4 | ii | Price of synthetic drugs at retail level, 2010 | Sources of information | /stats12/ppptab4b | ppptab4b | Table-PPP-04-partii.xml |
| Table | PPP | ppptab4 | 4 | iii | Price of synthetic drugs at retail level, 2010 | Geographical coverage / Methodology | /stats12/ppptab4c | ppptab4c | Table-PPP-04-partiii.xml |
| Table | PPP | ppptab5 | 5 | i | Potency of cannabis products at retail level, 2010 | Minimum, maximum, mean, median and modal potency recorded, measured as percentage of THC content | /stats12/ppptab5a | ppptab5a | Table-PPP-05-parti.xml |
| Table | PPP | ppptab5 | 5 | ii | Potency of cannabis products at retail level, 2010 | Sources of information | /stats12/ppptab5b | ppptab5b | Table-PPP-05-partii.xml |
| Table | PPP | ppptab5 | 5 | iii | Potency of cannabis products at retail level, 2010 | Geographical coverage / Sampling frame / Type of study | /stats12/ppptab5c | ppptab5c | Table-PPP-05-partiii.xml |
| Table | PPP | ppptab6 | 6 | i | Purity of heroin at retail level, 2010 | Minimum, maximum, mean, median and modal purity recorded (percentage) | /stats12/ppptab6a | ppptab6a | Table-PPP-06-parti.xml |
| Table | PPP | ppptab6 | 6 | ii | Purity of heroin at retail level, 2010 | Sources of information | /stats12/ppptab6b | ppptab6b | Table-PPP-06-partii.xml |
| Table | PPP | ppptab6 | 6 | iii | Purity of heroin at retail level, 2010 | Geographical coverage / Sampling frame / Type of study / Purity determined to base~salt | /stats12/ppptab6c | ppptab6c | Table-PPP-06-partiii.xml |
| Table | PPP | ppptab7 | 7 | i | Purity of cocaine products at retail level, 2010 | Minimum, maximum, mean, median and modal purity recorded (percentage) | /stats12/ppptab7a | ppptab7a | Table-PPP-07-parti.xml |
| Table | PPP | ppptab7 | 7 | ii | Purity of cocaine products at retail level, 2010 | Sources of information | /stats12/ppptab7b | ppptab7b | Table-PPP-07-partii.xml |
| Table | PPP | ppptab7 | 7 | iii | Purity of cocaine products at retail level, 2010 | Geographical coverage / Sampling frame / Type of study / Purity determined to base~salt | /stats12/ppptab7c | ppptab7c | Table-PPP-07-partiii.xml |
| Table | PPP | ppptab8 | 8 | i | Purity of synthetic drugs at retail level, 2010 | Minimum, maximum, mean, median and modal purity recorded | /stats12/ppptab8a | ppptab8a | Table-PPP-08-parti.xml |
| Table | PPP | ppptab8 | 8 | ii | Purity of synthetic drugs at retail level, 2010 | Sources of information | /stats12/ppptab8b | ppptab8b | Table-PPP-08-partii.xml |
| Table | PPP | ppptab8 | 8 | iii | Purity of synthetic drugs at retail level, 2010 | Geographical coverage / Sampling frame / Type of study | /stats12/ppptab8c | ppptab8c | Table-PPP-08-partiii.xml |
| Table | PPP | ppptab9 | 9 | i | Composition of illicit drug tablets, 2010 | Content of synthetic scheduled illicit drugs | /stats12/ppptab9a | ppptab9a | Table-PPP-09-parti.xml |
| Table | PPP | ppptab9 | 9 | ii | Composition of illicit drug tablets, 2010 | Sources of information | /stats12/ppptab9b | ppptab9b | Table-PPP-09-partii.xml |
| Table | PPP | ppptab9 | 9 | iii | Composition of illicit drug tablets, 2010 | Sampling frame / Type of monitoring system | /stats12/ppptab9c | ppptab9c | Table-PPP-09-partiii.xml |
| Table | PPP | ppptab9 | 9 | iv | Composition of illicit drug tablets, 2010 | Information available on substances listed in categories 'Miscellaneous' and 'Other' | /stats12/ppptab9d | ppptab9d | Table-PPP-09-partiv.xml |
| Table | PPP | ppptab9 | 9 | v | Composition of illicit drug tablets, 2010 | Information available on adulterants, cutting agents and/or impurities. | /stats12/ppptab9e | ppptab9e | Table-PPP-09-partv.xml |
| Figure | PPP | pppfig1 | 1 | Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2005–10 | /stats12/pppfig1 | pppfig1 | Table-PPP-01-parti.xml | ||
| Figure | PPP | pppfig2 | 2 | Indexed trends in EU potency/purity for major drug types, adjusting for population size, 2005-2010 | /stats12/pppfig2 | pppfig2 | Table-PPP-02-parti.xml | ||
| Table | SZR | szrtab0 | 0 | i | Seizures of illicit drugs | Data source: name of institution and name of monitoring system/study | /stats12/szrtab0a | szrtab0a | Table-SZR-00-parti.xml |
| Table | SZR | szrtab0 | 0 | ii | Seizures of illicit drugs | Methodological comments | /stats12/szrtab0b | szrtab0b | Table-SZR-00-partii.xml |
| Table | SZR | szrtab1 | 1 | Number of cannabis resin seizures, 1995 to 2010 | /stats12/szrtab1 | szrtab1 | Table-SZR-01-parti.xml | ||
| Table | SZR | szrtab2 | 2 | Quantities (kg) of cannabis resin seized, 1995 to 2010 | /stats12/szrtab2 | szrtab2 | Table-SZR-02-parti.xml | ||
| Table | SZR | szrtab3 | 3 | Number of herbal cannabis seizures, 1995 to 2010 | /stats12/szrtab3 | szrtab3 | Table-SZR-03-parti.xml | ||
| Table | SZR | szrtab4 | 4 | Quantities (kg) of herbal cannabis seized, 1995 to 2010 | /stats12/szrtab4 | szrtab4 | Table-SZR-04-parti.xml | ||
| Table | SZR | szrtab5 | 5 | Number of seizures of cannabis plants, 1995 to 2010 | /stats12/szrtab5 | szrtab5 | Table-SZR-05-parti.xml | ||
| Table | SZR | szrtab6 | 6 | i | Quantities (number of plants) of cannabis plants seized, 1995 to 2010 | Number of plants, 1995 to 2010 | /stats12/szrtab6a | szrtab6a | Table-SZR-06-parti.xml |
| Table | SZR | szrtab6 | 6 | ii | Quantities (Kg) of cannabis plants seized, 1995 to 2010 | Quantity (Kg) of plants, 1995 to 2010 | /stats12/szrtab6b | szrtab6b | Table-SZR-06-partii.xml |
| Table | SZR | szrtab7 | 7 | i | Number of heroin seizures 1995 to 2010 | 1995 to 2010 | /stats12/szrtab7a | szrtab7a | Table-SZR-07-parti.xml |
| Table | SZR | szrtab8 | 8 | i | Quantities (kg) of heroin seized 1995 to 2010 | 1995 to 2010 | /stats12/szrtab8a | szrtab8a | Table-SZR-08-parti.xml |
| Table | SZR | szrtab9 | 9 | i | Number of cocaine seizures 1995 to 2010 | 1995 to 2010 | /stats12/szrtab9a | szrtab9a | Table-SZR-09-parti.xml |
| Table | SZR | szrtab10 | 10 | i | Quantities (kg) of cocaine seized 1995 to 2010 | 1995 to 2010 | /stats12/szrtab10a | szrtab10a | Table-SZR-10-parti.xml |
| Table | SZR | szrtab11 | 11 | i | Number of amphetamine seizures 1995 to 2010 | 1995 to 2010 | /stats12/szrtab11a | szrtab11a | Table-SZR-11-parti.xml |
| Table | SZR | szrtab12 | 12 | i | Quantities (kg) of amphetamine seized 1995 to 2010 | Quantities (kg) of amphetamine, 1995 to 2010 | /stats12/szrtab12a | szrtab12a | Table-SZR-12-parti.xml |
| Table | SZR | szrtab12 | 12 | iii | Quantities (tablets) of amphetamine seized 1995 to 2010 | Quantity (tablets) of amphetamine, 1995 to 2010 | /stats12/szrtab12c | szrtab12c | Table-SZR-12-partiii.xml |
| Table | SZR | szrtab13 | 13 | i | Number of ecstasy seizures 1995 to 2010 | 1995 to 2010 | /stats12/szrtab13a | szrtab13a | Table-SZR-13-parti.xml |
| Table | SZR | szrtab14 | 14 | i | Quantities (tablets) of ecstasy seized 1995 to 2010 | Quantity (tablets) of ecstasy, 1995 to 2010 | /stats12/szrtab14a | szrtab14a | Table-SZR-14-parti.xml |
| Table | SZR | szrtab14 | 14 | ii | Quantities (Kg) of ecstasy seized 1995 to 2010 | Quantity (Kg) of ecstasy, 1995 to 2010 | /stats12/szrtab14b | szrtab14b | Table-SZR-14-partiii.xml |
| Table | SZR | szrtab15 | 15 | Number of LSD seizures 1995 to 2010 | 1995 to 2010 | /stats12/szrtab15 | szrtab15 | Table-SZR-15-parti.xml | |
| Table | SZR | szrtab16 | 16 | Quantities (units) of LSD seized 1995 to 2010 | 1995 to 2010 | /stats12/szrtab16 | szrtab16 | Table-SZR-16-parti.xml | |
| Table | SZR | szrtab17 | 17 | Number of methamphetamine seizures, 2001 to 2010 | /stats12/szrtab17 | szrtab17 | Table-SZR-17-parti.xml | ||
| Table | SZR | szrtab18 | 18 | Quantities (kg) of Methamphetamine seized 2001 to 2010 | /stats12/szrtab18 | szrtab18 | Table-SZR-18-parti.xml | ||
| Table | SZR | szrtab19 | 19 | Number of crack cocaine seizures, 1995-2010 | /stats12/szrtab19 | szrtab19 | Table-SZR-19-parti.xml | ||
| Table | SZR | szrtab20 | 20 | Quantities (kg) of crack cocaine seized 1995 to 2010 | /stats12/szrtab20 | szrtab20 | Table-SZR-20-parti.xml | ||
| Table | SZR | szrtab21 | 21 | i | Other substances seized, 2004 to 2010 | Other substances siezed not included in other SZR tables, 2004 to 2010 | /stats12/szrtab21a | szrtab21a | Table-SZR-21-parti.xml |
| Figure | SZR | szrfig1 | 1 | Estimated number of heroin seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2005-2010. | /stats12/szrfig1 | szrfig1 | Table-SZR-01-parti.xml | ||
| Figure | SZR | szrfig2 | 2 | Estimated number of cocaine seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2005-2010. | /stats12/szrfig2 | szrfig2 | Table-SZR-02-parti.xml | ||
| Table | TDI | tditab1 | 1 | Clients entering treatment and treatment units by country, 2010 or most recent year available | /stats12/tditab1 | tditab1 | Table-TDI-01-part0.xml | ||
| Table | TDI | tditab2 | 2 | i | Clients entering treatment and reporting treatment units, 1998 to 2010 | New clients by country and year of treatment | /stats12/tditab2a | tditab2a | Table-TDI-02-parti.xml |
| Table | TDI | tditab2 | 2 | ii | Clients entering treatment and reporting treatment units, 1998 to 2010 | All clients by country and year of treatment | /stats12/tditab2b | tditab2b | Table-TDI-02-partii.xml |
| Table | TDI | tditab2 | 2 | iii | Clients entering treatment and reporting treatment units, 1998 to 2010 | Reporting treatment units by country and year of treatment | /stats12/tditab2c | tditab2c | Table-TDI-02-partiii.xml |
| Table | TDI | tditab2 | 2 | iv | Clients entering treatment and reporting treatment units, 1998 to 2010 | Types of reporting treatment unit by country | /stats12/tditab2d | tditab2d | Table-TDI-02-partiv.xml |
| Table | TDI | tditab3 | 3 | i | New clients entering treatment by primary drug, 1998 to 2010 | New heroin clients by country and year of treatment (%) | /stats12/tditab3a | tditab3a | Table-TDI-03-parti.xml |
| Table | TDI | tditab3 | 3 | ii | New clients entering treatment by primary drug, 1998 to 2010 | New cocaine clients by country and year of treatment (%) | /stats12/tditab3b | tditab3b | Table-TDI-03-partii.xml |
| Table | TDI | tditab3 | 3 | iii | New clients entering treatment by primary drug, 1998 to 2010 | New stimulants (amphetamines and MDMA) clients by country and year of treatment (%) | /stats12/tditab3c | tditab3c | Table-TDI-03-partiii.xml |
| Table | TDI | tditab3 | 3 | iv | New clients entering treatment by primary drug, 1998 to 2010 | New cannabis clients by country and year of treatment (%) | /stats12/tditab3d | tditab3d | Table-TDI-03-partiv.xml |
| Table | TDI | tditab4 | 4 | i | Demographic characteristics of clients entering treatment, 2010 or most recent year available | New clients by country and gender (%) | /stats12/tditab4a | tditab4a | Table-TDI-04-parti.xml |
| Table | TDI | tditab4 | 4 | ii | Demographic characteristics of clients entering treatment, 2010 or most recent year available | All clients by country and gender (%) | /stats12/tditab4b | tditab4b | Table-TDI-04-partii.xml |
| Table | TDI | tditab4 | 4 | iii | Demographic characteristics of clients entering treatment, 2010 or most recent year available | New clients by country and age (%) | /stats12/tditab4c | tditab4c | Table-TDI-04-partiii.xml |
| Table | TDI | tditab4 | 4 | iv | Demographic characteristics of clients entering treatment, 2010 or most recent year available | All clients by country and age (%) | /stats12/tditab4d | tditab4d | Table-TDI-04-partiv.xml |
| Table | TDI | tditab5 | 5 | i | Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available | New clients by country and primary drug (%), regardless whether they inject the drug | /stats12/tditab5a | tditab5a | Table-TDI-05-parti.xml |
| Table | TDI | tditab5 | 5 | ii | Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available | All clients by country and primary drug (%), regardless whether they inject the drug | /stats12/tditab5b | tditab5b | Table-TDI-05-partii.xml |
| Table | TDI | tditab5 | 5 | iii | Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available | New clients by country and rates of injection of primary drug (%) | /stats12/tditab5c | tditab5c | Table-TDI-05-partiii.xml |
| Table | TDI | tditab5 | 5 | iv | Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available | All clients by country and rates of injection of primary drug (%) | /stats12/tditab5d | tditab5d | Table-TDI-05-partiv.xml |
| Table | TDI | tditab6 | 6 | Incidence of treatment demand for drug use, 2010 or most recent year available. New clients by country (rate per 100 000 population aged 15 to 64 years old) | /stats12/tditab6 | tditab6 | Table-TDI-06-part0.xml | ||
| Table | TDI | tditab7 | 7 | i | Data coverage, 2010 or most recent year available | Clients entering treatment by country and type of treatment centre and type of client | /stats12/tditab7a | tditab7a | Table-TDI-07-parti.xml |
| Table | TDI | tditab7 | 7 | ii | Data coverage, 2010 or most recent year available | Units by country and type of treatment centre and reporting status | /stats12/tditab7b | tditab7b | Table-TDI-07-partii.xml |
| Table | TDI | tditab8 | 8 | i | Primary use of stimulants of clients entering treatment, 2010 or most recent year available | New clients by country and type of stimulant (%) | /stats12/tditab8a | tditab8a | Table-TDI-08-parti.xml |
| Table | TDI | tditab8 | 8 | ii | Primary use of stimulants of clients entering treatment, 2010 or most recent year available | All clients by country and type of stimulant (%) | /stats12/tditab8b | tditab8b | Table-TDI-08-partii.xml |
| Table | TDI | tditab9 | 9 | i | Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available | New outpatient clients by country and gender | /stats12/tditab9a | tditab9a | Table-TDI-09-parti.xml |
| Table | TDI | tditab9 | 9 | ii | Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available | All outpatient clients by country and gender | /stats12/tditab9b | tditab9b | Table-TDI-09-partii.xml |
| Table | TDI | tditab9 | 9 | iii | Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available | New outpatient clients by country and age | /stats12/tditab9c | tditab9c | Table-TDI-09-partiii.xml |
| Table | TDI | tditab9 | 9 | iv | Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available | All outpatient clients by country and age | /stats12/tditab9d | tditab9d | Table-TDI-09-partiv.xml |
| Table | TDI | tditab10 | 10 | i | Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | New outpatient clients, age distribution by primary drug (%) | /stats12/tditab10a | tditab10a | Table-TDI-10-parti.xml |
| Table | TDI | tditab10 | 10 | ii | Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | New outpatient clients, primary drug distribution by age (%) | /stats12/tditab10b | tditab10b | Table-TDI-10-partii.xml |
| Table | TDI | tditab10 | 10 | iii | Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | All outpatient clients, age distribution by primary drug (%) | /stats12/tditab10c | tditab10c | Table-TDI-10-partiii.xml |
| Table | TDI | tditab10 | 10 | iv | Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | All outpatient clients, primary drug distribution by age (%) | /stats12/tditab10d | tditab10d | Table-TDI-10-partiv.xml |
| Table | TDI | tditab10 | 10 | v | Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | New inpatient clients, age distribution by primary drug (%) | /stats12/tditab10e | tditab10e | Table-TDI-10-partv.xml |
| Table | TDI | tditab10 | 10 | vi | Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | New inpatient clients, primary drug distribution by age (%) | /stats12/tditab10f | tditab10f | Table-TDI-10-partvi.xml |
| Table | TDI | tditab10 | 10 | vii | Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | All inpatient clients, age distribution by primary drug (%) | /stats12/tditab10g | tditab10g | Table-TDI-10-partvii.xml |
| Table | TDI | tditab10 | 10 | viii | Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | All inpatient clients, primary drug distribution by age (%) | /stats12/tditab10h | tditab10h | Table-TDI-10-partviii.xml |
| Table | TDI | tditab11 | 11 | i | Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | New outpatient clients, age at first use distribution by primary drug (%) | /stats12/tditab11a | tditab11a | Table-TDI-11-parti.xml |
| Table | TDI | tditab11 | 11 | ii | Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | New outpatient clients, primary drug distribution by age at first use (%) | /stats12/tditab11b | tditab11b | Table-TDI-11-partii.xml |
| Table | TDI | tditab11 | 11 | iii | Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | All outpatient clients, age at first use distribution by primary drug (%) | /stats12/tditab11c | tditab11c | Table-TDI-11-partiii.xml |
| Table | TDI | tditab11 | 11 | iv | Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | All outpatient clients, primary drug distribution by age at first use (%) | /stats12/tditab11d | tditab11d | Table-TDI-11-partiv.xml |
| Table | TDI | tditab11 | 11 | v | Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | New inpatient clients, age at first use distribution by primary drug (%) | /stats12/tditab11e | tditab11e | Table-TDI-11-partv.xml |
| Table | TDI | tditab11 | 11 | vi | Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | New inpatient clients, primary drug distribution by age at first use (%) | /stats12/tditab11f | tditab11f | Table-TDI-11-partvi.xml |
| Table | TDI | tditab11 | 11 | vii | Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | All inpatient clients, age at first use distribution by primary drug (%) | /stats12/tditab11g | tditab11g | Table-TDI-11-partvii.xml |
| Table | TDI | tditab11 | 11 | viii | Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available | All inpatient clients, primary drug distribution by age at first use (%) | /stats12/tditab11h | tditab11h | Table-TDI-11-partviii.xml |
| Table | TDI | tditab12 | 12 | i | Education status of clients entering treatment, 2010 or most recent year available | New outpatient clients by country and education status (%) | /stats12/tditab12a | tditab12a | Table-TDI-12-parti.xml |
| Table | TDI | tditab12 | 12 | ii | Education status of clients entering treatment, 2010 or most recent year available | All outpatient clients by country and education status (%) | /stats12/tditab12b | tditab12b | Table-TDI-12-partii.xml |
| Table | TDI | tditab12 | 12 | iii | Education status of clients entering treatment, 2010 or most recent year available | New inpatient clients by country and education status (%) | /stats12/tditab12c | tditab12c | Table-TDI-12-partiii.xml |
| Table | TDI | tditab12 | 12 | iv | Education status of clients entering treatment, 2010 or most recent year available | All inpatient clients by country and education status (%) | /stats12/tditab12d | tditab12d | Table-TDI-12-partiv.xml |
| Table | TDI | tditab13 | 13 | i | Labour status of clients entering treatment, 2010 or most recent year available | New outpatient clients by country and labour status (%) | /stats12/tditab13a | tditab13a | Table-TDI-13-parti.xml |
| Table | TDI | tditab13 | 13 | ii | Labour status of clients entering treatment, 2010 or most recent year available | All outpatient clients by country and labour status (%) | /stats12/tditab13b | tditab13b | Table-TDI-13-partii.xml |
| Table | TDI | tditab13 | 13 | iii | Labour status of clients entering treatment, 2010 or most recent year available | New inpatient clients by country and labour status (%) | /stats12/tditab13c | tditab13c | Table-TDI-13-partiii.xml |
| Table | TDI | tditab13 | 13 | iv | Labour status of clients entering treatment, 2010 or most recent year available | All inpatient clients by country and labour status (%) | /stats12/tditab13d | tditab13d | Table-TDI-13-partiv.xml |
| Table | TDI | tditab14 | 14 | i | Persons with whom client is living on entering treatment, 2010 or most recent year available | New outpatient clients by country and with whom living (%) | /stats12/tditab14a | tditab14a | Table-TDI-14-parti.xml |
| Table | TDI | tditab14 | 14 | ii | Persons with whom client is living on entering treatment, 2010 or most recent year available | All outpatient clients by country and with whom living (%) | /stats12/tditab14b | tditab14b | Table-TDI-14-partii.xml |
| Table | TDI | tditab14 | 14 | iii | Persons with whom client is living on entering treatment, 2010 or most recent year available | New inpatient clients by country and with whom living (%) | /stats12/tditab14c | tditab14c | Table-TDI-14-partiii.xml |
| Table | TDI | tditab14 | 14 | iv | Persons with whom client is living on entering treatment, 2010 or most recent year available | All inpatient clients by country and with whom living (%) | /stats12/tditab14d | tditab14d | Table-TDI-14-partiv.xml |
| Table | TDI | tditab15 | 15 | i | Type of accommodation of clients entering treatment, 2010 or most recent year available | New clients entering outpatient treatment by country and type of accommodation (%) | /stats12/tditab15a | tditab15a | Table-TDI-15-parti.xml |
| Table | TDI | tditab15 | 15 | ii | Type of accommodation of clients entering treatment, 2010 or most recent year available | All clients entering outpatient treatment by country and type of accommodation (%) | /stats12/tditab15b | tditab15b | Table-TDI-15-partii.xml |
| Table | TDI | tditab15 | 15 | iii | Type of accommodation of clients entering treatment, 2010 or most recent year available | New clients entering inpatient treatment by country and type of accommodation (%) | /stats12/tditab15c | tditab15c | Table-TDI-15-partiii.xml |
| Table | TDI | tditab15 | 15 | iv | Type of accommodation of clients entering treatment, 2010 or most recent year available | All clients entering inpatient treatment by country and type of accommodation (%) | /stats12/tditab15d | tditab15d | Table-TDI-15-partiv.xml |
| Table | TDI | tditab16 | 16 | i | Source of referral of clients entering treatment, 2010 or most recent year available | New outpatient clients by country and source of referral (%) | /stats12/tditab16a | tditab16a | Table-TDI-16-parti.xml |
| Table | TDI | tditab16 | 16 | ii | Source of referral of clients entering treatment, 2010 or most recent year available | All outpatient clients by country and source of referral (%) | /stats12/tditab16b | tditab16b | Table-TDI-16-partii.xml |
| Table | TDI | tditab16 | 16 | iii | Source of referral of clients entering treatment, 2010 or most recent year available | New inpatient clients by country and source of referral (%) | /stats12/tditab16c | tditab16c | Table-TDI-16-partiii.xml |
| Table | TDI | tditab16 | 16 | iv | Source of referral of clients entering treatment, 2010 or most recent year available | All inpatient clients by country and source of referral (%) | /stats12/tditab16d | tditab16d | Table-TDI-16-partiv.xml |
| Table | TDI | tditab17 | 17 | i | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | New opioid outpatient clients by country and usual route of administration (%) | /stats12/tditab17a | tditab17a | Table-TDI-17-parti.xml |
| Table | TDI | tditab17 | 17 | ii | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | All opioid outpatient clients by country and usual route of administration (%) | /stats12/tditab17b | tditab17b | Table-TDI-17-partii.xml |
| Table | TDI | tditab17 | 17 | iii | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | New cocaine (HCl and crack) outpatient clients by country and usual route of administration (%) | /stats12/tditab17c | tditab17c | Table-TDI-17-partiii.xml |
| Table | TDI | tditab17 | 17 | iv | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | All cocaine (HCl and crack) outpatient clients by country and usual route of administration (%) | /stats12/tditab17d | tditab17d | Table-TDI-17-partiv.xml |
| Table | TDI | tditab17 | 17 | ix | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | New cannabis outpatient clients by country and usual route of administration (%) | /stats12/tditab17i | tditab17i | Table-TDI-17-partix.xml |
| Table | TDI | tditab17 | 17 | v | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | New stimulants (other than cocaine) outpatient clients by country and usual route of administration (%) | /stats12/tditab17e | tditab17e | Table-TDI-17-partv.xml |
| Table | TDI | tditab17 | 17 | vi | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | All stimulants (other than cocaine) outpatient clients by country and usual route of administration (%) | /stats12/tditab17f | tditab17f | Table-TDI-17-partvi.xml |
| Table | TDI | tditab17 | 17 | vii | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | New hypnotics and sedatives outpatient clients by country and usual route of administration (%) | /stats12/tditab17g | tditab17g | Table-TDI-17-partvii.xml |
| Table | TDI | tditab17 | 17 | viii | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | All hypnotics and sedatives outpatient clients by country and usual route of administration (%) | /stats12/tditab17h | tditab17h | Table-TDI-17-partviii.xml |
| Table | TDI | tditab17 | 17 | x | Route of administration by primary drug of clients entering treatment, 2010 or most recent year available | All cannabis outpatient clients by country and usual route of administration (%) | /stats12/tditab17j | tditab17j | Table-TDI-17-partx.xml |
| Table | TDI | tditab18 | 18 | i | Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available | New outpatient clients by primary drug and frequency of use (%) | /stats12/tditab18a | tditab18a | Table-TDI-18-parti.xml |
| Table | TDI | tditab18 | 18 | ii | Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available | All outpatient clients by primary drug and frequency of use (%) | /stats12/tditab18b | tditab18b | Table-TDI-18-partii.xml |
| Table | TDI | tditab18 | 18 | iii | Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available | New inpatient clients by primary drug and frequency of use (%) | /stats12/tditab18c | tditab18c | Table-TDI-18-partiii.xml |
| Table | TDI | tditab18 | 18 | iv | Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available | All inpatient clients by primary drug and frequency of use (%) | /stats12/tditab18d | tditab18d | Table-TDI-18-partiv.xml |
| Table | TDI | tditab19 | 19 | i | Primary drug of clients entering treatment, 2010 or most recent year available | New outpatient clients by country and primary drug (%) | /stats12/tditab19a | tditab19a | Table-TDI-19-parti.xml |
| Table | TDI | tditab19 | 19 | ii | Primary drug of clients entering treatment, 2010 or most recent year available | All outpatient clients by country and primary drug (%) | /stats12/tditab19b | tditab19b | Table-TDI-19-partii.xml |
| Table | TDI | tditab19 | 19 | iii | Primary drug of clients entering treatment, 2010 or most recent year available | New inpatient clients by country and primary drug (%) | /stats12/tditab19c | tditab19c | Table-TDI-19-partiii.xml |
| Table | TDI | tditab19 | 19 | iv | Primary drug of clients entering treatment, 2010 or most recent year available | All inpatient clients by country and primary drug (%) | /stats12/tditab19d | tditab19d | Table-TDI-19-partiv.xml |
| Table | TDI | tditab21 | 21 | i | Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available | New outpatient clients, ratio of males to females by country and primary drug | /stats12/tditab21a | tditab21a | Table-TDI-21-parti.xml |
| Table | TDI | tditab21 | 21 | ii | Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available | All outpatient clients, ratio of males to females by country and primary drug | /stats12/tditab21b | tditab21b | Table-TDI-21-partii.xml |
| Table | TDI | tditab21 | 21 | iii | Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available | New inpatient clients, ratio of males to females by country and primary drug | /stats12/tditab21c | tditab21c | Table-TDI-21-partiii.xml |
| Table | TDI | tditab21 | 21 | iv | Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available | All inpatient clients, ratio of males to females by country and primary drug | /stats12/tditab21d | tditab21d | Table-TDI-21-partiv.xml |
| Table | TDI | tditab22 | 22 | i | Secondary drugs cited by clients entering treatment, 2010 or most recent year available | Outpatient units | /stats12/tditab22a | tditab22a | Table-TDI-22-parti.xml |
| Table | TDI | tditab22 | 22 | ii | Secondary drugs cited by clients entering treatment, 2010 or most recent year available | Inpatient units | /stats12/tditab22b | tditab22b | Table-TDI-22-partii.xml |
| Table | TDI | tditab24 | 24 | i | Type of treatment centre by primary drug of clients entering treatment, 2010 or most recent year available | New clients by country and primary drug and type of treatment centre (%) | /stats12/tditab24a | tditab24a | Table-TDI-24-parti.xml |
| Table | TDI | tditab24 | 24 | ii | Type of treatment centre by primary drug of clients entering treatment, 2010 or most recent year available | All clients by country and primary drug and type of treatment centre (%) | /stats12/tditab24b | tditab24b | Table-TDI-24-partii.xml |
| Table | TDI | tditab25 | 25 | Age distribution of all clients entering outpatient treatment by primary drug and gender, 2010 or most recent year available | /stats12/tditab25 | tditab25 | Table-TDI-25-part0.xml | ||
| Table | TDI | tditab32 | 32 | i | Mean age of clients entering treatment by primary drug and gender, 2010 or most recent year available | Outpatient clients | /stats12/tditab32a | tditab32a | Table-TDI-32-parti.xml |
| Table | TDI | tditab32 | 32 | ii | Mean age of clients entering treatment by primary drug and gender, 2010 or most recent year available | Inpatient clients | /stats12/tditab32b | tditab32b | Table-TDI-32-partii.xml |
| Table | TDI | tditab33 | 33 | i | Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2010 or most recent year available | Outpatient units | /stats12/tditab33a | tditab33a | Table-TDI-33-parti.xml |
| Table | TDI | tditab33 | 33 | ii | Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2010 or most recent year available | Inpatient units | /stats12/tditab33b | tditab33b | Table-TDI-33-partii.xml |
| Table | TDI | tditab36 | 36 | Primary amphetamine use among new clients entering treatment (%), 2005 to 2010 | /stats12/tditab36 | tditab36 | Table-TDI-36-part0.xml | ||
| Table | TDI | tditab37 | 37 | i | Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available | All clients by country and primary drug and type of treatment unit | /stats12/tditab37a | tditab37a | Table-TDI-37-parti.xml |
| Table | TDI | tditab37 | 37 | ii | Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available | Outpatient clients by primary drug and mean age, gender ratio | /stats12/tditab37b | tditab37b | Table-TDI-37-partii.xml |
| Table | TDI | tditab37 | 37 | iii | Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available | Inpatient clients by primary drug and mean age, gender ratio | /stats12/tditab37c | tditab37c | Table-TDI-37-partiii.xml |
| Table | TDI | tditab37 | 37 | iv | Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available | Outpatient clients by secondary drug and primary drug | /stats12/tditab37d | tditab37d | Table-TDI-37-partiv.xml |
| Table | TDI | tditab37 | 37 | v | Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available | Inpatient clients by secondary drug and primary drug | /stats12/tditab37e | tditab37e | Table-TDI-37-partv.xml |
| Table | TDI | tditab102 | 102 | i | New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | New opioid outpatient clients by country and age | /stats12/tditab102a | tditab102a | Table-TDI-102-parti.xml |
| Table | TDI | tditab102 | 102 | ii | New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | New cocaine (HCI and 'crack') outpatient clients by country and age | /stats12/tditab102b | tditab102b | Table-TDI-102-partii.xml |
| Table | TDI | tditab102 | 102 | iii | New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | New stimulants (other than cocaine) outpatient clients by country and age | /stats12/tditab102c | tditab102c | Table-TDI-102-partiii.xml |
| Table | TDI | tditab102 | 102 | iv | New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | New hallucinogen outpatient clients by country and age | /stats12/tditab102d | tditab102d | Table-TDI-102-partiv.xml |
| Table | TDI | tditab102 | 102 | v | New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | New hypnotics and sedatives outpatient clients by country and age | /stats12/tditab102e | tditab102e | Table-TDI-102-partv.xml |
| Table | TDI | tditab102 | 102 | vi | New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | New volatile inhalant outpatient clients by country and age | /stats12/tditab102f | tditab102f | Table-TDI-102-partvi.xml |
| Table | TDI | tditab102 | 102 | vii | New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | New cannabis outpatient clients by country and age | /stats12/tditab102g | tditab102g | Table-TDI-102-partvii.xml |
| Table | TDI | tditab102 | 102 | viii | New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | New 'other drugs' outpatient clients by country and by age | /stats12/tditab102h | tditab102h | Table-TDI-102-partviii.xml |
| Table | TDI | tditab103 | 103 | i | All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | All opioid outpatient clients by country and age | /stats12/tditab103a | tditab103a | Table-TDI-103-parti.xml |
| Table | TDI | tditab103 | 103 | ii | All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | All cocaine (HCI and 'crack') outpatient clients by country and age | /stats12/tditab103b | tditab103b | Table-TDI-103-partii.xml |
| Table | TDI | tditab103 | 103 | iii | All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | All stimulants (other than cocaine) outpatient clients by country and age | /stats12/tditab103c | tditab103c | Table-TDI-103-partiii.xml |
| Table | TDI | tditab103 | 103 | iv | All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | All hallucinogen outpatient clients by country and age | /stats12/tditab103d | tditab103d | Table-TDI-103-partiv.xml |
| Table | TDI | tditab103 | 103 | v | All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | All hypnotics and sedatives outpatient clients by country and age | /stats12/tditab103e | tditab103e | Table-TDI-103-partv.xml |
| Table | TDI | tditab103 | 103 | vi | All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | All volatile inhalant outpatient clients by country and age | /stats12/tditab103f | tditab103f | Table-TDI-103-partvi.xml |
| Table | TDI | tditab103 | 103 | vii | All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | All cannabis outpatient clients by country and age | /stats12/tditab103g | tditab103g | Table-TDI-103-partvii.xml |
| Table | TDI | tditab103 | 103 | viii | All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available | All 'other drugs' outpatient clients by country and by age | /stats12/tditab103h | tditab103h | Table-TDI-103-partviii.xml |
| Table | TDI | tditab104 | 104 | i | New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | New opioid inpatient clients by country and age | /stats12/tditab104a | tditab104a | Table-TDI-104-parti.xml |
| Table | TDI | tditab104 | 104 | ii | New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | New cocaine (HCI and 'crack') inpatient clients by country and age | /stats12/tditab104b | tditab104b | Table-TDI-104-partii.xml |
| Table | TDI | tditab104 | 104 | iii | New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | New stimulants (other than cocaine) inpatient clients by country and age | /stats12/tditab104c | tditab104c | Table-TDI-104-partiii.xml |
| Table | TDI | tditab104 | 104 | iv | New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | New hallucinogen inpatient clients by country and age | /stats12/tditab104d | tditab104d | Table-TDI-104-partiv.xml |
| Table | TDI | tditab104 | 104 | v | New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | New hypnotics and sedatives inpatient clients by country and age | /stats12/tditab104e | tditab104e | Table-TDI-104-partv.xml |
| Table | TDI | tditab104 | 104 | vi | New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | New volatile inhalant inpatient clients by country and age | /stats12/tditab104f | tditab104f | Table-TDI-104-partvi.xml |
| Table | TDI | tditab104 | 104 | vii | New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | New cannabis inpatient clients by country and age | /stats12/tditab104g | tditab104g | Table-TDI-104-partvii.xml |
| Table | TDI | tditab104 | 104 | viii | New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | New 'other drugs' inpatient clients by country and by age | /stats12/tditab104h | tditab104h | Table-TDI-104-partviii.xml |
| Table | TDI | tditab105 | 105 | i | All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | All opioid inpatient clients by country and age | /stats12/tditab105a | tditab105a | Table-TDI-105-parti.xml |
| Table | TDI | tditab105 | 105 | ii | All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | All cocaine (HCI and 'crack') inpatient clients by country and age | /stats12/tditab105b | tditab105b | Table-TDI-105-partii.xml |
| Table | TDI | tditab105 | 105 | iii | All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | All stimulants (other than cocaine) inpatient clients by country and age | /stats12/tditab105c | tditab105c | Table-TDI-105-partiii.xml |
| Table | TDI | tditab105 | 105 | iv | All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | All hallucinogen inpatient clients by country and age | /stats12/tditab105d | tditab105d | Table-TDI-105-partiv.xml |
| Table | TDI | tditab105 | 105 | v | All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | All hypnotics and sedatives inpatient clients by country and age | /stats12/tditab105e | tditab105e | Table-TDI-105-partv.xml |
| Table | TDI | tditab105 | 105 | vi | All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | All volatile inhalant inpatient clients by country and age | /stats12/tditab105f | tditab105f | Table-TDI-105-partvi.xml |
| Table | TDI | tditab105 | 105 | vii | All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | All cannabis inpatient clients by country and age | /stats12/tditab105g | tditab105g | Table-TDI-105-partvii.xml |
| Table | TDI | tditab105 | 105 | viii | All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available | All 'other drugs' inpatient clients by country and by age | /stats12/tditab105h | tditab105h | Table-TDI-105-partviii.xml |
| Table | TDI | tditab106 | 106 | i | New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | New opioid outpatient clients by country and age at first use | /stats12/tditab106a | tditab106a | Table-TDI-106-parti.xml |
| Table | TDI | tditab106 | 106 | ii | New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | New cocaine (HCI and 'crack') outpatient clients by country and age at first use | /stats12/tditab106b | tditab106b | Table-TDI-106-partii.xml |
| Table | TDI | tditab106 | 106 | iii | New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | New stimulants (other than cocaine) outpatient clients by country and age at first use | /stats12/tditab106c | tditab106c | Table-TDI-106-partiii.xml |
| Table | TDI | tditab106 | 106 | iv | New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | New hallucinogen outpatient clients by country and age at first use | /stats12/tditab106d | tditab106d | Table-TDI-106-partiv.xml |
| Table | TDI | tditab106 | 106 | v | New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | New hypnotics and sedatives outpatient clients by country and age at first use | /stats12/tditab106e | tditab106e | Table-TDI-106-partv.xml |
| Table | TDI | tditab106 | 106 | vi | New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | New volatile inhalant outpatient clients by country and age at first use | /stats12/tditab106f | tditab106f | Table-TDI-106-partvi.xml |
| Table | TDI | tditab106 | 106 | vii | New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | New cannabis outpatient clients by country and age at first use | /stats12/tditab106g | tditab106g | Table-TDI-106-partvii.xml |
| Table | TDI | tditab106 | 106 | viii | New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | New 'other drugs' outpatient clients by country and by age at first use | /stats12/tditab106h | tditab106h | Table-TDI-106-partviii.xml |
| Table | TDI | tditab107 | 107 | i | All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | All opioid outpatient clients by country and age at first use | /stats12/tditab107a | tditab107a | Table-TDI-107-parti.xml |
| Table | TDI | tditab107 | 107 | ii | All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | All cocaine (HCI and 'crack') outpatient clients by country and age at first use | /stats12/tditab107b | tditab107b | Table-TDI-107-partii.xml |
| Table | TDI | tditab107 | 107 | iii | All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | All stimulants (other than cocaine) outpatient clients by country and age at first use | /stats12/tditab107c | tditab107c | Table-TDI-107-partiii.xml |
| Table | TDI | tditab107 | 107 | iv | All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | All hallucinogen outpatient clients by country and age at first use | /stats12/tditab107d | tditab107d | Table-TDI-107-partiv.xml |
| Table | TDI | tditab107 | 107 | v | All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | All hypnotics and sedatives outpatient clients by country and age at first use | /stats12/tditab107e | tditab107e | Table-TDI-107-partv.xml |
| Table | TDI | tditab107 | 107 | vi | All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | All volatile inhalant outpatient clients by country and age at first use | /stats12/tditab107f | tditab107f | Table-TDI-107-partvi.xml |
| Table | TDI | tditab107 | 107 | vii | All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | All cannabis outpatient clients by country and by age at first use | /stats12/tditab107g | tditab107g | Table-TDI-107-partvii.xml |
| Table | TDI | tditab107 | 107 | viii | All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available | All 'other drugs' outpatient clients by country and by age at first use | /stats12/tditab107h | tditab107h | Table-TDI-107-partviii.xml |
| Table | TDI | tditab108 | 108 | i | New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | New opioid inpatient clients by country and age at first use | /stats12/tditab108a | tditab108a | Table-TDI-108-parti.xml |
| Table | TDI | tditab108 | 108 | ii | New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | New cocaine (HCI and 'crack') inpatient clients by country and age at first use | /stats12/tditab108b | tditab108b | Table-TDI-108-partii.xml |
| Table | TDI | tditab108 | 108 | iii | New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | New stimulants (other than cocaine) inpatient clients by country and age at first use | /stats12/tditab108c | tditab108c | Table-TDI-108-partiii.xml |
| Table | TDI | tditab108 | 108 | iv | New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | New hallucinogen inpatient clients by country and age at first use | /stats12/tditab108d | tditab108d | Table-TDI-108-partiv.xml |
| Table | TDI | tditab108 | 108 | v | New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | New hypnotics and sedatives inpatient clients by country and age at first use | /stats12/tditab108e | tditab108e | Table-TDI-108-partv.xml |
| Table | TDI | tditab108 | 108 | vi | New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | New volatile inhalant inpatient clients by country and age at first use | /stats12/tditab108f | tditab108f | Table-TDI-108-partvi.xml |
| Table | TDI | tditab108 | 108 | vii | New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | New cannabis inpatient clients by country and age at first use | /stats12/tditab108g | tditab108g | Table-TDI-108-partvii.xml |
| Table | TDI | tditab108 | 108 | viii | New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | New 'other drugs' inpatient clients by country and age at first use | /stats12/tditab108h | tditab108h | Table-TDI-108-partviii.xml |
| Table | TDI | tditab109 | 109 | i | All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | All opioid inpatient clients by country and age at first use | /stats12/tditab109a | tditab109a | Table-TDI-109-parti.xml |
| Table | TDI | tditab109 | 109 | ii | All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | All cocaine (HCI and 'crack') inpatient clients by country and age at first use | /stats12/tditab109b | tditab109b | Table-TDI-109-partii.xml |
| Table | TDI | tditab109 | 109 | iii | All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | All stimulants (other than cocaine) inpatient clients by country and age at first use | /stats12/tditab109c | tditab109c | Table-TDI-109-partiii.xml |
| Table | TDI | tditab109 | 109 | iv | All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | All hallucinogen inpatient clients by country and age at first use | /stats12/tditab109d | tditab109d | Table-TDI-109-partiv.xml |
| Table | TDI | tditab109 | 109 | v | All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | All hypnotics and sedatives inpatient clients by country and age at first use | /stats12/tditab109e | tditab109e | Table-TDI-109-partv.xml |
| Table | TDI | tditab109 | 109 | vi | All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | All volatile inhalant inpatient clients by country and age at first use | /stats12/tditab109f | tditab109f | Table-TDI-109-partvi.xml |
| Table | TDI | tditab109 | 109 | vii | All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | All cannabis inpatient clients by country and age at first use | /stats12/tditab109g | tditab109g | Table-TDI-109-partvii.xml |
| Table | TDI | tditab109 | 109 | viii | All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available | All 'other drugs' inpatient clients by country and by age at first use | /stats12/tditab109h | tditab109h | Table-TDI-109-partviii.xml |
| Table | TDI | tditab111 | 111 | i | Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available | New opioid outpatient clients by country and frequency of use (%) | /stats12/tditab111a | tditab111a | Table-TDI-111-parti.xml |
| Table | TDI | tditab111 | 111 | ii | Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available | All opioid outpatient clients by country and frequency of use (%) | /stats12/tditab111b | tditab111b | Table-TDI-111-partii.xml |
| Table | TDI | tditab111 | 111 | iii | Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available | New cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%) | /stats12/tditab111c | tditab111c | Table-TDI-111-partiii.xml |
| Table | TDI | tditab111 | 111 | iv | Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available | All cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%) | /stats12/tditab111d | tditab111d | Table-TDI-111-partiv.xml |
| Table | TDI | tditab111 | 111 | v | Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available | New stimulants (other than cocaine) outpatient clients by country and frequency of use (%) | /stats12/tditab111e | tditab111e | Table-TDI-111-partv.xml |
| Table | TDI | tditab111 | 111 | vi | Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available | All stimulants (other than cocaine) outpatient clients by country and frequency of use (%) | /stats12/tditab111f | tditab111f | Table-TDI-111-partvi.xml |
| Table | TDI | tditab111 | 111 | vii | Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available | New cannabis outpatient clients by country and frequency of use (%) | /stats12/tditab111g | tditab111g | Table-TDI-111-partvii.xml |
| Table | TDI | tditab111 | 111 | viii | Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available | All cannabis outpatient clients by country and frequency of use (%) | /stats12/tditab111h | tditab111h | Table-TDI-111-partviii.xml |
| Table | TDI | tditab112 | 112 | i | Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available | New opioid inpatient clients by country and frequency of use (%) | /stats12/tditab112a | tditab112a | Table-TDI-112-parti.xml |
| Table | TDI | tditab112 | 112 | ii | Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available | All opioid inpatient clients by country and frequency of use (%) | /stats12/tditab112b | tditab112b | Table-TDI-112-partii.xml |
| Table | TDI | tditab112 | 112 | iii | Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available | New cannabis inpatient clients by country and frequency of use (%) | /stats12/tditab112c | tditab112c | Table-TDI-112-partiii.xml |
| Table | TDI | tditab112 | 112 | iv | Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available | All cannabis inpatient clients by country and frequency of use (%) | /stats12/tditab112d | tditab112d | Table-TDI-112-partiv.xml |
| Table | TDI | tditab112 | 112 | v | Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available | New stimulants (other than cocaine) inpatient clients by country and frequency of use (%) | /stats12/tditab112e | tditab112e | Table-TDI-112-partv.xml |
| Table | TDI | tditab112 | 112 | vi | Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available | All stimulants (other than cocaine) inpatient clients by country and frequency of use (%) | /stats12/tditab112f | tditab112f | Table-TDI-112-partvi.xml |
| Table | TDI | tditab112 | 112 | vii | Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available | New cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%) | /stats12/tditab112g | tditab112g | Table-TDI-112-partvii.xml |
| Table | TDI | tditab112 | 112 | viii | Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available | All cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%) | /stats12/tditab112h | tditab112h | Table-TDI-112-partviii.xml |
| Table | TDI | tditab113 | 113 | All clients entering treatment for opioids by country and type of opioid misused (%), 2010 or most recent year available | /stats12/tditab113 | tditab113 | Table-TDI-113-part0.xml | ||
| Table | TDI | tditab114 | 114 | Primary opioids distribution among all clients entering treatment by country and type of treatment centre (%), 2010 | /stats12/tditab114 | tditab114 | Table-TDI-114-part0.xml | ||
| Table | TDI | tditab115 | 115 | i | HCL and Crack use of clients entering outpatient treatment , 2010 or most recent year available | New outpatient clients by country and type of cocaine product | /stats12/tditab115a | tditab115a | Table-TDI-115-parti.xml |
| Table | TDI | tditab115 | 115 | ii | HCL and Crack use of clients entering outpatient treatment , 2010 or most recent year available | All outpatient clients by country and type of cocaine product | /stats12/tditab115b | tditab115b | Table-TDI-115-partii.xml |
| Figure | TDI | tdifig1 | 1 | i | Trend in estimated number of new clients entering treatment by selected primary drugs, 2005 to 2010 | Percentage by primary drug | /stats12/tdifig1a | tdifig1a | Table-TDI-g01-parti.xml |
| Figure | TDI | tdifig1 | 1 | ii | Trend in estimated number of new clients entering treatment by primary drug used, from 2005 to 2010 | Numbers of clients by primary drug | /stats12/tdifig1b | tdifig1b | Table-TDI-g01-partii.xml |
| Figure | TDI | tdifig2 | 2 | i | New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants and other drugs in 2010. | New clients | /stats12/tdifig2a | tdifig2a | Table-TDI-g02-parti.xml |
| Figure | TDI | tdifig2 | 2 | ii | New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants and other drugs in 2010. | All clients | /stats12/tdifig2b | tdifig2b | Table-TDI-g02-partii.xml |
| Figure | TDI | tdifig3 | 3 | i | Trend in estimated number of all clients entering treatment by selected primary drug used, 2005 to 2010 | Percentage by primary drug | /stats12/tdifig3a | tdifig3a | Table-TDI-g03-parti.xml |
| Figure | TDI | tdifig3 | 3 | ii | Trend in estimated number of all clients entering treatment by selected primary drugs, 2005 to 2010 | Numbers of clients by primary drug | /stats12/tdifig3b | tdifig3b | Table-TDI-g03-partii.xml |
| Figure | TDI | tdifig7 | 7 | New outpatient clients injecting opioid as primary drug from 2005 to 2010 in 18 countries supplying data | /stats12/tdifig7 | tdifig7 | Table-TDI-g07-part0.xml |